

# **CURRICULUM VITAE**

**David A. Lewis**

**November 2025**

**Table of Contents**

PERSONAL DETAILS	3
PROFESSIONAL REGISTRATION	3
EDUCATION	3
QUALIFICATIONS	3
PRESENT APPOINTMENTS	4
PREVIOUS APPOINTMENTS	4
PRIZES & AWARDS	6
PROFESSIONAL EXPERIENCE	7
WORK WITH THE WORLD HEALTH ORGANIZATION (WHO)	10
WORK WITH THE GLOBAL ANTIBIOTIC R&D PARTNERSHIP (GARDP)	13
WORK WITH THE SOUTHERN AFRICAN DEVELOPMENT COMMUNITY	13
WORK WITH THE SOUTH AFRICAN NATIONAL DEPARTMENT OF HEALTH	13
WORK WITH THE DEPARTMENT OF HEALTH, AUSTRALIA	14
WORK WITH THE NEW SOUTH WALES MINISTRY OF HEALTH, AUSTRALIA	14
WORK WITH THE INTERNATIONAL SOCIETY FOR INFECTIOUS DISEASES (ISID)	15
WORK WITH THE INTERNATIONAL UNION AGAINST SEXUALLY TRANSMITTED INFECTIONS (IUSTI)	15
WORK WITH THE INTERNATIONAL SOCIETY FOR SEXUALLY TRANSMITTED DISEASES RESEARCH (ISSTD)	15
WORK WITH THE AUSTRALASIAN SOCIETY FOR HIV, VIRAL HEPATITIS AND SEXUALLY TRANSMISSIBLE INFECTIONS (ASHM)	15
WORK WITH THE NSW MULTICULTURAL HIV AND HEPATITIS SERVICE ADVISORY BOARD	16
WORK WITH THE AUSTRALASIAN CHAPTER OF SEXUAL HEALTH MEDICINE	16
WORK WITH BRITISH ASSOCIATION OF SEXUAL HEALTH & HIV (BASHH)	16
WORK WITH OTHER STEERING COMMITTEES AND ADVISORY BOARDS	16
WORK WITH CONFERENCE ORGANIZING COMMITTEES	17
WORK WITH JOURNALS	18
WORK WITH COMMUNITY GROUPS	19
MEDIA LIAISON	20
SURVEILLANCE EXPERIENCE	20
GUIDELINE DEVELOPMENT	21
TEACHING EXPERIENCE	22
PhD and MSc SUPERVISIONS	23
PhD and MSc EXAMINER APPOINTMENTS	24
RESEARCH EXPERIENCE	25
AWARDED RESEARCH GRANTS	27
PUBLICATIONS IN PEER-REVIEWED JOURNALS	31
BOOK CONTRIBUTIONS	49
LETTERS	49
INVITED PRESENTATIONS	51

## PERSONAL DETAILS

Name: David Arthur LEWIS

Work Address: Western Sydney Sexual Health Centre,  
Level 4 Jeffrey House,  
162 Marsden Street,  
Parramatta NSW 2150,  
Australia

Home Address: 3 Keppel Road, Ryde, NSW 2112, Australia

Telephone: +61 437304035 (mobile)  
+61 2 9762 5388 (work)

E-mail: [david.lewis2@sydney.edu.au](mailto:david.lewis2@sydney.edu.au)

Dual nationality: UK Citizen, Australian Citizen

## PROFESSIONAL REGISTRATION

Registration with the Medical Board of Australia (AHPRA)

- AHPRA Reg. No. MED0001909302
- Registered as a Medical Practitioner with Specialist Registration (Sexual Health Medicine) from 25 May 2015

## EDUCATION

- Abingdon School, UK (1972-80)
- St. John's College, Oxford University (pre-clinical studies), UK (1981-84)
- London Hospital Medical College, London University (clinical studies), UK (1984-87)

## QUALIFICATIONS

- 11 'O' levels, 1 GCSE and 3 'A' levels
- BA Honours degree in Physiological Sciences (Oxford) 1984
- MB BS (London) 1987
- Diploma in Tropical Medicine and Hygiene (London) 1990
- MRCP (UK) 1993

- MSc in Clinical Microbiology (London) 1993
- Diploma in Family Planning (London) 1994
- Diploma in Genitourinary Medicine (London) 1996 (with distinction)
- UK Certificate of Completion of Specialist Training in Genitourinary Medicine 2000
- PhD (London) 2000
- Diploma of Imperial College for Genitourinary Medicine (London) 2001
- FRCP (UK) 2005
- FACHSHM (Australia) 2015

## **PRESENT APPOINTMENTS**

- Director, Western Sydney Sexual Health Centre, Western Sydney Local Health District, Parramatta, Australia (01.09.2014 to date)
- Conjoint Professor, Westmead Clinical School, Faculty of Medicine and Health & Marie Bashir Institute for Infectious Diseases and Biosecurity, University of Sydney, Australia (01.09.2014 to date)
- Honorary Professor, Division of Medical Virology, Department of Pathology, Faculty of Health Sciences, University of Cape Town, South Africa (01.05.2019 to date)
- Adjunct Professor, Curtin School of Population Health, Faculty of Health Sciences, Curtin University, Australia (30.09.2025 to date)

## **PREVIOUS APPOINTMENTS**

- |                    |  |
|--------------------|--|
| 01.8.87 to 31.1.88 | House Physician to Dr. A. Brain (General Medicine), Dr. Raychaudhury (Infectious Diseases) and Dr. R. Fowler (Medicine for the Elderly) at Rush Green Hospital, Romford                  |
| 01.2.88 to 31.7.88 | House Surgeon to Mr. R.A. Roxburgh at Broomfield Hospital, Chelmsford  |
| 01.2.89 to 31.7.89 | SHO in Infectious Diseases to Dr. W.R.C. Weir, Dr. B. Bannister and Dr. H. Smith at the Royal Free Hospital's Department of Infectious Diseases based at Coppett's Wood Hospital, London |

01.8.89 to 31.1.90	SHO in Haematology to Dr. D.W. Milligan and Dr. M.J. Leyland at East Birmingham Hospital, Birmingham
01.2.90 to 31.7.90	SHO in General Medicine to Dr. B.H.B. Robinson at East Birmingham Hospital, Birmingham
01.8.90 to 31.1.91	SHO in GUM and HIV Medicine to Dr. M. Shahmanesh at Birmingham General Hospital, Birmingham
01.2.91 to 18.7.93	Registrar in Medical Microbiology, Royal London Hospital Trust/Newham Healthcare rotation
19.7.93 to 01.8.93	SHO (locum) in Neurology to Dr. D. Wren, Dr. F. Schon, and Dr. M. Brown at Atkinson Morley's Hospital for Neurological Diseases, London
20.9.93 to 11.1.94	Senior Registrar (locum) in Infectious Diseases to Dr. B. Bannister and Dr. W.R.C. Weir at the Royal Free Hospital's Department of Infectious Diseases based at Coppett's Wood Hospital, London
14.1.94 to 22.5.94	Registrar in Medical Microbiology, Royal London Hospital Trust/Newham Healthcare rotation, London
01.6.94 to 30.6.94	Locum Registrar in GUM, St. Mary's Hospital, London
01.7.94 to 31.7.95	Registrar in GUM and HIV, St. Mary's Hospital and Central Middlesex Hospital rotation, London
01.8.95 to 10.9.95	Senior Registrar (locum) in GUM and HIV, St. Mary's Hospital & Central Middlesex Hospital rotation, London
11.9.95 to 13.4.97	Senior Registrar in GUM and HIV, St. Mary's Hospital & Central Middlesex Hospital rotation, London
14.4.97 to 13.04.00	Wellcome Trust Research Fellow in Clinical Tropical Medicine, Imperial College School of Medicine, St. Mary's Campus, London and University of Texas Southwestern Medical Center, Dallas
14.4.00 to 02.08.00	Specialist Registrar in GUM and HIV, St. Mary's Hospital, Central Middlesex Hospital rotation, London
11.09.00 to 30.09.01	Senior Lecturer and Honorary Consultant Physician in GUM and HIV at Guy's, King's and St. Thomas's School of Medicine, London
01.10.01 to 11.03.02	Consultant Physician in GUM and HIV (locum) at Central Middlesex Hospital, London

- 08.04.02 to 04.08.04 Consultant Physician in HIV and GUM at Guy's and St. Thomas' NHS Trust, London
- 01.11.04 to 31.12.11 Head of the Sexually Transmitted Infections Reference Centre, National Institute for Communicable Diseases, a Division of the National Health Laboratory Service, Johannesburg, South Africa.
- 01.01.12 to 30.06.14 Head of the Centre for HIV and Sexually Transmitted Infections, National Institute for Communicable Diseases, a Division of the National Health Laboratory Service, Johannesburg
- 06.03.06 to 30.06.14 Associate Professor, Department of Internal Medicine, School of Clinical Medicine, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg
- 01.12.05 to 30.06.14 Adjunct member of the Institute of Infectious Diseases and Molecular Medicine, University of Cape Town, Cape Town

### **PRIZES AND AWARDS (Individual)**

- Brazilian Sexually Transmitted Diseases Society's Walter Belda Gold Medal (2019)
- International Union against Sexually Transmitted Infections' Gold Medal (2017)
- National Health Laboratory Service Best Research Output Award (2013)
- International Union against Sexually Transmitted Infections' Silver Medal (2009)
- Wellcome Trust Training Fellowship in Clinical Tropical Medicine (1997-2000)
- Caverness Travelling Scholarship awarded by the Jefferiss Trust (1996)
- Riker Prize for the best medical student elective report (1987)

### **PRIZES AND AWARDS (Team)**

- QuWest Quality Award (Category: Health Research) (2024)
- QuWest Quality Award (Category: Keeping People Healthy) (2024)
- Achievements in Integrated and Community Excellence Quality Award (2024)
- Westmead Hospital Excellence Award (2020)

**PROFESSIONAL EXPERIENCE****1. Genitourinary Medicine (GUM) and HIV (UK)**

- SHO in GUM/HIV, Birmingham General Hospital, UK (6 months)
- GUM sessional work at Newham General Hospital as a Microbiology Registrar (1 weekly session for 6 months)
- Registrar in GUM/HIV at St. Mary's and Central Middlesex Hospitals (13 months)
- Senior Registrar in GUM/HIV at St. Mary's and Central Middlesex Hospitals (21 months)
- Specialist Registrar in GUM/HIV at St. Mary's and Central Middlesex Hospitals (4 months)
- Senior Lecturer in GUM/HIV at King's College Hospital (13 months)
- Locum Consultant in GUM/HIV at Central Middlesex Hospital (5 months)
- Consultant in GUM/HIV at Guy's and St. Thomas' NHS Trust (28 months)

*Experience/expertise within specialty of GUM/HIV in the UK:*

- Basic and complex STI case management, management of genital discharge and ulcer disease, management of syphilis at all stages, cervical screening and treatment of anogenital warts, penile dermatoses, Behçet's syndrome
- HIV out-patient management from AZT monotherapy to modern HAART, including pregnant women
- HIV in-patient management at trainee and consultant level in London teaching hospitals from early in the UK AIDS epidemic through to the HAART era
- Post-exposure prophylaxis for HIV
- Screening and vaccination for hepatitis A and B
- STI/HIV care for men-who-have-sex-with-men (consultant lead)
- Primary care STI management liaison role (consultant lead)
- Sexual assault case management
- Young people's work
- Outreach STI work with young Afro-Caribbean men

**2. Sexually-Transmitted Infections and HIV (Middle and Lower Income Countries)**

- Bangkok's Hospital for Venereal Diseases (1 month, 1988)

- South African Institute for Medical Research and the National Reference Centre for Sexually Transmitted Diseases, Johannesburg, South Africa (3 months in 1996/1997)
- Attended STD/HIV clinics in various Brazilian Cities (2 weeks, 2002/2003)
- Clinical research, surveillance and clinical care for STI/HIV patients as part of activities at the Centre for HIV and STIs at the National Institute for Communicable Diseases (9 years and 8 months, 2004-2014)

*Experience/expertise within specialty of GUM/HIV in Middle/Lower Income Countries:*

- Basic and complex STI case management with the syndromic management approach, management of genital discharge and tropical ulcer disease, management of syphilis at all stages, management of HPV-related disease in low income countries
- Management of complicated STIs in HIV patients, HIV screening and referral to HIV treatment services, HIV rapid testing
- Outreach STI work with men in living in South Africa's mining communities

**3. Sexually-Transmitted Infections, HIV and viral hepatitis (Australia)**

- Western Sydney Sexual Health Centre (September 2014 to date)

*Experience/expertise within specialty of GUM/HIV/hepatitis in Australia:*

- Basic and complex STI case management, management of all stages of syphilis
- Clinical management of HIV patients including HIV patients co-infected with hepatitis B and C
- HIV PreP and HIV PEP provision for men-who-have-sex-with men and other at risk individuals
- DoxyPEP provision for men-who-have-sex-with men
- Screening (hepatitis A/B/C) and vaccination (hepatitis A/B)
- Cervical screening (Pap smears, HPV testing) for women living with HIV and female sex workers
- Management of HIV/STI/hepatitis co-infections among patients from NSW Health's defined priority populations, including men-who-have-sex-with men, transgender patients, sex workers, intravenous drug users and members of the Aboriginal and Torres Strait Islander community
- HIV/STI/hepatitis screening for men-who-have-sex-with-men, transgender individuals and women at high risk at a local sex-on-premises venue



#### 4. Infectious Diseases and Tropical Medicine

- House Physician, Regional Infectious Diseases' Unit, Rush Green Hospital (6 months)
- SHO at the Regional Infectious Diseases' Unit at Coppett's Wood Hospital (6 months)
- SHO at East Birmingham Hospital's Bone Marrow Transplant Unit (6 months)
- Locum Senior Registrar on the Regional Infectious Diseases' Unit at Coppett's Wood Hospital (4 months)
- Student elective to study leprosy in Tamil Nadu, South India (8 weeks, 1987)
- Microbiology Department of Peradeniya University Hospital, Sri Lanka (2 weeks, 1992)
- On call management advice for rabies, viral haemorrhagic fevers, meningitis, food-borne outbreaks, diarrhoeal and other diseases, South Africa (2004-2014)
- Diploma in Tropical Medicine and Hygiene (1990)

##### *Experience/expertise within specialty of infectious diseases:*

- Basic and complex management of patients with viral hepatitis, meningitis, diarrhoeal disease, pneumonia and tropical infections including rabies, viral haemorrhagic fevers, schistosomiasis and malaria. Management of infectious diseases, including fungal infections, in neutropenic patients.

#### 5. Microbiology

- Microbiology Registrar at the Royal London NHS Trust and Newham General and St. Andrew's Hospital Trust, UK (28 months)
- Virology Registrar at the Royal London NHS Trust, UK (6 months)
- Wellcome Trust-funded PhD on the molecular pathogenesis of chancroid (36 months)
- Head of the Centre for HIV and STIs/STI Reference Centre at the National Institute for Communicable Diseases (NHLS), South Africa (9 years and 8 months)

##### *Experience/expertise within STI/HIV/hepatitis-associated microbiology:*

- Routine diagnostic bacteriology and virology techniques, including genital specimen examination by Gram stain and dark field microscopy, antimicrobial susceptibility testing for *Neisseria gonorrhoeae* (phenotypic/genotypic) and *Treponema pallidum* (genotypic), ELISA and other laboratory-based serology (HIV, viral hepatitis, syphilis), rapid test technology for outreach screening (HIV, syphilis, trichomoniasis), nucleic acid amplification and real-time PCR, gonococcal typing by plasmid profile, auxotype, serovar, ribotype and NG-MAST, molecular typing of *Treponema pallidum* and human papillomavirus, cell culture (chlamydia and HSV diagnosis, attachment assays, cytotoxicity)

experiments), temperature-dependent rabbit model for *Haemophilus ducreyi* experimental infection

## **6. Public health**

- UK National Chlamydial Screening Programme local steering group member (2003)
- Chair of UK National Syphilis Guideline Committee (2003)
- National hotline on-call consultant (1 in 9 rota) for outbreaks and public health emergencies (2004-2014)
- STI treatment guideline writing at national (South Africa), regional (Southern African Development Community, Namibia) and international (World health Organization) levels (2005 to date)
- Temporary technical advisor appointments with the World Health Organization (2005 to date) and Southern African Development Community (2009)
- Task team member for South African National Sexual Assault guidelines (2010)
- Review of the 2010 HIV Management Guidelines for Adults in South Africa (2010)
- Member of the NSW Ministry of Health's HIV Strategy (2012-2015) Implementation Committee (2015-2016)
- Member of the NSW Ministry of Health's Dried Blood Spot Pilot Program Working Group (2015-2018)
- Chair of the NSW Health Publicly Funded Sexual Health Clinic Directors' Leadership Group (2019 to date)
- Member, NSW Ministry of Health's HIV Strategy Implementation Committee (2021-2026)
- Member, NSW Ministry of Health's STI Strategy Implementation Committee (2021-2026)
- Member, NSW Ministry of Health's HIV Data Advisory Group (2023-date)

## **WORK WITH THE WORLD HEALTH ORGANIZATION (WHO)**

- WHO temporary technical advisor at the WHO/LSHTM/Population Council consultation on guidelines for Periodic Presumptive Treatment (PPT) interventions for STIs, London (September 2005)
- Member of working group for informal UNICEF/UNDP/World Bank/WHO Special Programme for Research and Training in Tropical Diseases (TDR)/STD Diagnostics Initiative (SDI) consultation on guidelines for the use of syphilis rapid tests guidelines in Atlanta, USA (January 2006)

- WHO temporary technical advisor at the orientation meeting for “Integration of comprehensive STI case control management into curricula of medical schools and training institutions for nurses and midwives” in Harare, Zimbabwe (March 2006)
- WHO temporary technical advisor at the “Acceleration of HIV prevention in Africa: strengthening control of sexually transmitted infections” meeting in Harare, Zimbabwe (April 2006)
- WHO temporary technical advisor at the informal WHO-AFRO consultation on “The use of syphilis rapid tests” in Harare, Zimbabwe (April 2006)
- WHO temporary technical advisor invited to set up microbiological STI surveillance in Windhoek, Namibia (June 2006 and March 2007)
- WHO temporary technical advisor at the meeting of stakeholders for the “Action Plan: Implementation of the Global Strategy for the prevention and control of STIs” in Geneva, Switzerland (June 2006)
- WHO temporary technical advisor at the meeting of stakeholders for the development of new WHO STI guidelines, including genital ulceration and male urethritis syndromes in Montreux, Switzerland (April 2008)
- Member of the WHO Expert Advisory Panel for Global Surveillance of Antimicrobial Resistance in *Neisseria gonorrhoeae* (May 2009 to February 2012)
- Member of editorial team to review and update the WHO laboratory manual entitled *Laboratory diagnosis of sexually transmitted infections, including human immunodeficiency virus* (December 2009 to July 2013)
- WHO temporary technical advisor at the joint WHO/CDC consultation on “The strategic response to the threat of untreatable *Neisseria gonorrhoeae* and emergence of cephalosporin resistance in *Neisseria gonorrhoeae*” in Manila, Philippines (April 2010)
- WHO temporary technical advisor invited to set up gonococcal susceptibility surveillance in Harare, Zimbabwe (October 2010)
- WHO temporary technical advisor invited to plan establishment of gonococcal susceptibility surveillance in Mwanza, Tanzania (November 2010)
- WHO temporary technical advisor invited to assist with microbiological STI surveillance in Antananarivo, Madagascar (December 2010)
- WHO temporary technical advisor and co-organiser of the Workshop to review progress of Gonococcal Antimicrobial Surveillance Programme (GASP) Activities in the WHO African Region, Harare, Zimbabwe (March–April 2011)
- WHO temporary technical advisor for “Global implementation of the Gonococcal Antimicrobial Susceptibility Programme (GASP)” in Geneva, Switzerland (June 2011)

- Participation in technical consultation to discuss a WHO document entitled “Technical Guide for countries to set targets for HIV prevention, treatment and care for sex workers, men who have sex with men and transgender people” (May 2013)
- WHO temporary technical advisor/member, STI Guideline Development Group Meeting in Geneva, Switzerland (December 2013)
- WHO temporary technical advisor for “Point of care tests for sexually transmitted infections” in Annecy, France (May 2014)
- WHO temporary technical for the Partners meeting on Antimicrobial resistance in *N. gonorrhoeae* and STI surveillance, Geneva, Switzerland (August 2014)
- WHO temporary technical advisor for the Technical Advisory Group for Sexually Transmitted Infections in Geneva, Switzerland (August 2014)
- WHO temporary technical advisor/member, STI Guideline Development Group Meeting in Geneva, Switzerland (October 2015)
- Participant at the joint WHO-Drugs for Neglected Diseases Initiative’s Global Antibiotic Research and Development Partnership meeting, Geneva, Switzerland, June 2016
- Participant at the joint WHO-Drugs for Neglected Diseases Initiative’s Global Antibiotic Research and Development Partnership meeting, Montreux, Switzerland, March 2017
- WHO temporary technical advisor/member, STI Guideline Development Group Meeting in Geneva, Switzerland (August 2017)
- WHO temporary technical advisor, 3rd Technical Consultation on Point-Of-Care Tests for Sexually transmitted Infections in Verona, Italy (December 2019)
- Sub-group meeting of the STI Guideline Development Group on syndromic case management, Virtual Meeting (July 2020)
- WHO temporary technical advisor, STI Guideline Development Group Meeting, Virtual Meeting, (September & October, 2020)
- Observer, Virtual meeting of the WHO Strategic and Technical Advisory Committee on HIV and Viral Hepatitis (STAC-HIVHEP) (October 2020)
- Advisor (STAC-HHS member), Virtual meeting of the WHO Strategic and Technical Advisory Committee on HIV, Viral Hepatitis and Sexually Transmitted Infections (STAC-HHS) (September 2021)
- Expert Group Member, WHO Global AMR Research Agenda in the Human Health Sector (July 2022 to date)
- WHO temporary technical advisor/member, WHO Consolidated Guidelines on STI Prevention and Care, STI Guideline Development Group virtual meeting (May-June 2023)

- Advisor (STAC-HHS member), Meeting of the WHO Strategic and Technical Advisory Committee on HIV, Viral Hepatitis and Sexually Transmitted Infections (STAC-HHS) (November 2023)
- WHO temporary technical advisor/member, WHO Consolidated Guidelines on STI Prevention and Care, STI Guideline Development Group virtual meeting (April 2024)
- WHO temporary technical advisor/member, WHO Consolidated Guidelines on STI Prevention and Care, STI Guideline Development Group virtual meeting (September 2024)
- Advisor (STAC-HHS member), Meeting of the WHO Strategic and Technical Advisory Committee on HIV, Viral Hepatitis and Sexually Transmitted Infections (STAC-HHS) (November 2024)

### **WORK WITH THE GLOBAL ANTIBIOTIC RESEARCH & DEVELOPMENT PARTNERSHIP (GARDP)**

- Member of the Expert Group of the Antimicrobial Memory Recovery Initiative (AMRI), a programme of the Global Antibiotic R&D Partnership (2017-date)
- Member of the Zoliflodacin Phase III Advisory Panel, Global Antibiotic Research and Development Partnership (GARDP) (2017-2019)
- Participation in the GARDP Expert Meeting on *Mycoplasma genitalium* (September 2024)

### **WORK WITH THE SOUTHERN AFRICAN DEVELOPMENT COMMUNITY (SADC)**

- Technical Expert at the SADC technical meeting to review the draft Framework for the Management of Sexually Transmitted Infections in Livingstone, Zambia (September 2009)

### **WORK WITH THE NATIONAL DEPARTMENT OF HEALTH, SOUTH AFRICA**

- Co-opted to the Essential Drugs Programme Primary Health Care sub-committee to assist in the revision of the National STI Guideline revision process (2007-2008)
- Member, Technical Task Team to revise the National Sexual Assault Guidelines (Maternal and Child Health Directorate, NDoH) (2009-10)
- Member, South African National AIDS Council's Technical Task Team for Sustaining Health and Wellness (formerly for the Technical Task Team for Treatment, Care and Support) (2011-2014)

- Member, NDoH commissioned Expert HPV group which wrote technical guidance for the National Advisory Group on Immunizations in respect of HPV vaccination prior to the launch of the NDoH tender (2013)
- Co-opted to the Essential Drugs Programme Primary Health Care sub-committee to assist in the revision of the National STI Guideline revision process (2014)

## **WORK WITH THE NATIONAL DEPARTMENT OF HEALTH, AUSTRALIA**

- Seconded to the Communicable Diseases Network Australia Committee to assist with the Multi-drug Resistant Gonorrhoea Response Plan (2018)
- Member, Gonorrhoea Treatment Guidelines Working Group established by the Communicable Diseases Network Australia Committee to assist with the Multi-drug Resistant Gonorrhoea Response Plan (2018-2023)
- Member, Australian Centre for Disease Control's extensively Drug-Resistant (XDR) and Multi-drug (MDR) Gonorrhoea Working Group (2023-date)
- Chair, NSW Health Gonorrhoea Response Workshop (2025)

## **WORK WITH THE NEW SOUTH WALES MINISTRY OF HEALTH, AUSTRALIA**

- Member, NSW Ministry of Health's HIV Data Advisory Group (2023-date)
- Member, NSW Ministry of Health's HIV Strategy Implementation Committee (2021-2026)
- Member, NSW Ministry of Health's STI Strategy Implementation Committee (2021-2026)
- Member, NSW Ministry of Health's HIV Strategy Implementation Committee (2015-2016)
- Member, NSW Ministry of Health's Dried Blood Spot Pilot Program Working Group (2015-2018)
- Member, Sexual Health Medicine Model Scope of Clinical Practice Working Group, State Scope of Clinical Practice Unit (2017-2018)
- Chair, NSW Health Publicly Funded Sexual Health Clinic Directors' Leadership Group (2019 to date)

## **WORK WITH THE INTERNATIONAL SOCIETY FOR INFECTIOUS DISEASES (ISID)**

- Elected Council Member (2020 to date)
- Research Capacity Building Mentor for Melissa Nkeng Asongha (May 2024-April 2025)
- Review of ISID grant applications

## **WORK WITH THE INTERNATIONAL UNION AGAINST SEXUALLY TRANSMITTED INFECTIONS (IUSTI)**

- IUSTI-Africa Regional Director (2005–2013)
- IUSTI-World President (2013-2017)
- IUSTI-World Immediate Past President (2017-2019)
- Member, IUSTI-World Executive Committee (2005-2019)
- Senior Counsellor, IUSTI-World Executive Committee (2019 to date)
- Honorary Advisor, IUSTI-Asia Pacific Regional Committee (2025 to date)

## **WORK WITH THE INTERNATIONAL SOCIETY FOR SEXUALLY TRANSMITTED DISEASES RESEARCH (ISSTD)**

- Elected Member, International Executive Committee (2007-2013)
- IUSTI Observer, International Executive Committee (2013-2017)

## **WORK WITH THE AUSTRALASIAN SOCIETY FOR HIV, VIRAL HEPATITIS AND SEXUAL HEALTH MEDICINE (ASHM)**

- Member of the ASHM International Advisory Board (2015 to date)
- Member of the ASHM COVID-19 Taskforce's Regional Advisory Group (2020 to date)
- Speaker at an ASHM-organized 'HIV PrEP and other hot topics in HIV & STIs' educational session for General Practitioners, Western Sydney (20 June 2018)
- Member of the Reference Committee, Doxy-PEP Clinical Guideline
- Member of the Expert Advisory Group, STI Testing Frequency Guideline

## **WORK WITH THE NSW MULTICULTURAL HIV AND HEPATITIS SERVICE ADVISORY BOARD**

- Member of the NSW MHAHS Advisory Group (2023-2024)

## **WORK WITH THE AUSTRALASIAN CHAPTER OF SEXUAL HEALTH MEDICINE (AChSHM), ROYAL AUSTRALASIAN COLLEGE OF PHYSICIANS (RACP)**

- Member of the AChSHM Organizing Committee for the 2017 Annual Scientific Meeting and Trainee's Day Programme Committee (August 2016-March 2017)
- Review of the Sexual Health Laboratory Methods Logbook for Trainees (July 2017)
- Examiner for the AChSHM Exit Exam (August 2022)

## **WORK WITH THE BRITISH ASSOCIATION FOR SEXUAL HEALTH AND HIV (BASHH) [formerly MEDICAL SOCIETY FOR THE STUDY OF VENEREAL DISEASES (MSSVD)]**

- Member of the Bacterial Special Interest Group (BSIG) (1997-2002) and Adolescent Special Interest Group (ASIG) (2002 to 2004)
- Co-lead in the development of the ASIG/Faculty of Family Planning Joint Proposal for a NICE guideline on Young People's Sexual Health Services
- BSIG's Steering Group for the UK National Screening and Testing Guidelines for STIs
- Chair of the Revision Group for the UK Early and Late Syphilis Guidelines
- Co-established and taught on the BSIG microscopy course (1997-2002)
- Lecturer and Day Organiser of the BASHH Course for STIs and HIV

## **WORK WITH OTHER STEERING COMMITTEES & ADVISORY BOARDS**

- Member, Endpoint Adjudication Committee, Biyela trial of Bexsero immunization in young women in Africa funded by the Bill and Melinda Gates Foundation (2024-date)
- Member of the Strategic Advisory Committee for the ARC Industrial Transformation Research Hub on Antimicrobial Resistance (2023-2024)



- Member of the Sexual Health Surveillance Network Committee (ACCESS), Kirby Institute (2014 to 2018)
- Member, Sexual Health ACCESS STI Surveillance Network Committee, Kirby and Burnet Institutes (2023 to date)
- Member of the Advisory Board for the Blood-Borne Virus and STI Research, Intervention and Strategic Evaluation (BRISE) programme of policy-relevant research to support the New South Wales population health response to HIV, STIs and viral hepatitis prevention, treatment and care (Sexual Health Directors' representative) (2015-2018)
- Chair of the External Advisory Group, NHMRC Centre for Research Excellence in Aboriginal Sexual Health and Blood Borne Viruses (2016-2020)
- Member, Advisory Group for Great Britain's National Survey of Sexual Attitudes and Lifestyles (NATSAL), funded by the Wellcome Trust's Longitudinal Population Studies (April 2018 to date)
- Chairperson, Scientific Advisory Board for the EDCTP-funded GIFT-Africa consortium (October 2021 to date)
- Member, Endpoint Adjudication Committee, Gates-funded trial of Bexsero vaccination among women in South Africa (June 2024 to date)

## **WORK WITH CONFERENCE ORGANISING COMMITTEES**

- Member, Organizing Committee for the 1<sup>st</sup> Congress of the Federation of Infectious Diseases Societies of South Africa (FIDSSA), Sun City, South Africa, July 24-27, 2005
- Member, International Steering Committee, 15<sup>th</sup> International Conference on AIDS and STIs in Africa (ICASA), Dakar, Senegal, December 8-11, 2008
- Chair, Basic Science Track, 18<sup>th</sup> International Society for STD Research (ISSTD) conference, London, UK, June 28 – July 1 2009
- Co-Chair, STI Track, 3<sup>rd</sup> Meeting of the Federation of Infectious Diseases Societies of Southern Africa (FIDSSA), Sun City, South Africa, 20-23 August, 2009
- Conference Chairperson, 2009 International Union against STIs (IUSTI) World meeting, Cape Town, South Africa, 9-12 November 2009
- Member, Abstract Review Committee for Antibiotic Resistance, International Pathogenic *Neisseria* Conference 2010, Banff, Canada, 11-16 September 2010
- Co-Chair, Scientific Committee, 13<sup>th</sup> International Union against STIs (IUSTI) World Congress, Melbourne, Australia, 15-17 October 2012

- Co-Chair, Basic Science Track Sub-Committee, Joint 20th International Society for STD Research (ISSTD) conference and 14<sup>th</sup> International Union against STIs (IUSTI) World Congress, Vienna, Austria, 14-17 July 2013
- Member, Local Organizing Committee, 16<sup>th</sup> International Congress on Infectious Diseases, Cape Town, South Africa, 2-5 April, 2014
- Co-Chair, 15<sup>th</sup> International Union against STIs (IUSTI) World Congress, held in association with the 2014 STD Prevention Conference and the 2nd Latin American IUSTI-ALACITS Congress, Atlanta, USA, 9-12 June 2014
- Member, International Scientific Committee, 18<sup>th</sup> IUSTI Asia Pacific Conference, Bangkok, Thailand, 12-15 November 2014
- Co-Chair and Member, Local Organizing Committee, Joint 21st International Society for STD Research (ISSTD) conference and 16<sup>th</sup> International Union against STIs (IUSTI) World Congress, Brisbane, Australia, 13-16 September 2015
- Member, International Scientific Programme Steering Committee, 17<sup>th</sup> IUSTI World Congress, Marrakesh, Morocco, 9-11 May 2016
- Co-Chair, Joint 22nd International Society for STD Research (ISSTD) conference and 18<sup>th</sup> International Union against STIs (IUSTI) World Congress, Rio de Janeiro, Brazil, 9-12 September 2017
- Co-Chair, International Scientific Committee, Joint 23rd International Society for STD Research (ISSTD) conference and 20<sup>th</sup> International Union against STIs (IUSTI) World Congress, Vancouver, Canada, 14-17 July 2019
- Chair, Scholarship Committee, 23<sup>rd</sup> IUSTI World Congress, Victoria Falls, Zimbabwe, 4-7 September 2022
- Member, Local Organizing Committee and Scientific Advisory Panel, 22<sup>nd</sup> International Pathogenic *Neisseria* Conference, Cape Town, South Africa, 9-14 October 2022
- Member, Abstract Review Committee, International Pathogenic *Neisseria* Conference 2023, Boston, USA, 11-16 September 2023
- Member, Clinical Track Team, 25<sup>th</sup> IUSTI World Congress, Sydney, Australia, 17-20 September 2023
- Member, International Advisory Committee for the 20<sup>th</sup> International Conference on Infectious Diseases, Cape Town, South Africa 3-6 December 2024

## WORK WITH JOURNALS

- Editorial Board Member, *Sexually Transmitted Infections* (2003 to date)

- Deputy Editor for *Sexually Transmitted Infections* (2003-2016)
- Editor, Tropical Medicine Series, *Sexually Transmitted Infections* (2001-2007)
- Editor, Special Issue on Men's Sexual Health, *Sexually Transmitted Infections* (2004)
- Co-Editor, Special Issue on *Trichomonas vaginalis* Infection, *Sexually Transmitted Infections* (2013)
- Joint Editor for *Sexual Health* (2005-2020)
- Reviewer for *AIDS Patient Care and STDs*, *BMC Infectious Diseases*, *Brazilian Journal of Infectious Diseases*, *Emerging Infectious Diseases*, *Expert Review of Anti-infective Therapy*, *Family Practice*, *Future Medicine*, *International Journal of STD & AIDS*, *Journal of Antimicrobial Chemotherapy*, *Journal of Infectious Diseases*, *Journal of Medical Internet Research*, *Journal of Medical Virology*, *Lancet HIV*, *PLOS Medicine*, *Sexual Health*, *Sexually Transmitted Infections*, *Sexually Transmitted Diseases*, *South African Journal of Epidemiology and Infection*

## WORK WITH COMMUNITY GROUPS

- Sessional doctor in past with London Brook, a specialist service for contraceptive and sexual health services for young people
- Established the 374 clinic for young men, an outreach STI clinical service held at Brixton Brook's premises
- Coordination of the King's Healthcare NHS Trust contribution to Noh Budget Films' presentation "The Big Issue", a peer group education project for young people based in Lambeth. This project resulted in a video documentary and a theatre performance dramatizing young people's attitudes and concerns to sexual health.
- Steering group member for "The Playa's Club", a collaborative project between Noh Budget Films and Blackliners to raise awareness of sexual health, promote social inclusion and improve the life opportunities of Young Black Men aged 16-19 in the borough of Lambeth. A video was produced for use in local schools which includes the processes involved in a young man's visit to a GUM clinic
- Director and Trustee of NAZ Project, a voluntary sector organization working in the sexual health field with clients from Asia, the Horn of Africa and Latin America (2001-2004)
- Work with the NAZ Vida HIV support group for Portuguese speaking clients
- Support group work with local professionals and community groups to address the needs of African and Afro-Caribbean men having sex with men in South London
- Member of the Asian Gay Men's Action Group, hosted by AIDS Council of New South Wales (ACON) (2015-date)
- Member of Positive Life NSW's Brains Trust (2020-date)

- HIV prevention talks and judge at the Miss Mardi Gras International Queen competition (2021, 2023, 2024, 2025)
- Speaker for Positive Life NSW's Patient Advocacy Workshop (April 2024)

## **MEDIA LIAISON**

- SABC radio – Syphilis (19 February 2010)
- Medical chronicle – Untreatable gonorrhoea: a new epidemic (July 2012)
- Australian Doctor - Fears over untreatable gonorrhoea (17 October 2012)
- News Hour on BBC World Service – Resistance to gonorrhoea in Africa (23 April 2013)
- Contribution to ABC news article entitled 'STIs are increasing in Australia. Can anything lower these rates?', available at <https://www.abc.net.au/news/2025-04-19/sti-increasing-australia-lower-rates/105169548> (19 April 2025)

## **SURVEILLANCE EXPERIENCE**

- Co-ordinator for the 2002 and 2003 'Sexual Health Survey of Gay Men in London' at the Guy's and St. Thomas' NHS Trust site
- Initiation, planning and implementation of a National Microbiological Surveillance Programme for South Africa (2004-2014)
- Technical assistance with the National Clinical Surveillance Programme for South Africa (2004-2014)
- Technical assistance with the National Microbiological Surveillance Programme for Swaziland (2003-04, 2005-06, 2013-2014)
- Technical assistance with the National Microbiological Surveillance Programme for Lesotho (2006-07)
- Assistance with the National Microbiological Surveillance Programme for Namibia (2006-08, 2013-2014)
- Technical assistance with gonococcal resistance and male urethritis aetiological surveillance in Zimbabwe (2009 – 2012)
- Technical assistance with the gonococcal resistance and STI syndrome aetiological surveillance in Madagascar (2010 – 2012)

## GUIDELINE DEVELOPMENT

- Revision of the internal GUM guidelines at Guy's and St/ Thomas' NHS Trust GUM guidelines with the Head of Service (2003)
- Chair of the Revision of the BASHH Clinical Effectiveness Group's Guideline on Early and Late Syphilis (2003)
- Member of BASHH BSIG's Steering Group for the UK National Screening and Testing Guidelines for STIs (2005-2006)
- Technical advisor for the planned revision of the World Health Organisation's STI Treatment Guidelines (2008)
- Technical advisor for the revision of the Namibian National STI Guidelines (2008)
- Expert advisor to the Essential Drugs Programme Primary Care Sub-Committee to revise the 2003 South African National STI Treatment guidelines (2008)
- Member of the Task Team for the Revision of the South African National Sexual Assault Guidelines (2009 to 2011)
- Technical advisor for the revision of the STI Framework for Management and Treatment of the Southern African Development Community (SADC, 15 member states, 2009-2010)
- Co-opted to work with the Treatment, Care and Technical Task Team in assisting with the development of the National Department of Health's Strategic Plan for HIV/AIDS, TB and STIs for 2012-2016 (2011)
- Expert advisor to the Essential Drugs Programme Primary Care Sub-Committee to lead on the re-drafting of the 2008 South African National Guidelines for Sexually Transmitted Infections (2012-date)
- Revision of Section 3.9.4 on *Haemophilus ducreyi* culture for the Aerobic Bacteriology section in the Clinical Microbiology Procedures Handbook (2013)
- Member of WHO STI Guideline Development Group (2013 to date)
- Reviewed chapters on genital ulceration and gonorrhoea for Healthcare Pathway STI guidelines for local GPs (2014-2015)
- Member of the Gonorrhoea Treatment Guidelines Working Group established by the Communicable Diseases Network Australia Committee to assist with the Multi-drug Resistant Gonorrhoea Response Plan (2018)
- Reviewed chapter on HIV PrEP for Healthcare Pathway STI guidelines for local GPs (2019)
- Reviewed chapters on Sexual Health advice, Sexual Health assessment, chlamydia and syphilis for Healthcare Pathway STI guidelines for local GPs (2020)

- Reviewed chapters on HIV diagnosis for Healthcare Pathway STI guidelines for local GPs (2021)
- External expert invited to support the revision of the US Centers for Disease Control and Prevention's (CDC) Division of STD Prevention's STI Treatment Guidelines (genital ulcer disease and ectoparasite section) (2024-2025)
- Member of the Reference Committee, Doxy-PEP Clinical Guideline
- Member of the Expert Advisory Group, STI Testing Frequency Guideline

## TEACHING EXPERIENCE

- Nurses, nurse practitioners, medical undergraduates and postgraduates (lectures, clinics, practical classes, wards and tutorials) in UK, South Africa and Australia.
- I designed a special study module (SSM) in clinical aspects of STDs at GKT School of Medicine, London, UK. I also re-organized of the medical students' GUM attachment at King's College Hospital, UK.
- General practitioners and family planning doctors (lectures, clinics, workshops) in UK.
- I designed and implemented a one day training course for general practitioners and nurses in South Africa.
- Surveillance training of nurses, microbiology laboratory staff and Department of health officials in South Africa, Namibia, Lesotho, Swaziland, Zimbabwe and Madagascar.
- I designed and participated in one day and 2 week annual STI laboratory and clinical training courses for Microbiology and Infectious Diseases registrars in South Africa.
- Co-founder of the BASHH BSIG's Microscopy course for Genitourinary Medicine in UK as well as lecturer and day course organiser on the BASHH Course on STIs and HIV.
- Lecturer on the Masters of Medicine (HIV, STI and Sexual Health), University of Sydney, covering the following topics: gonorrhoea, chlamydial infection, *Mycoplasma genitalium* infection, *Ureaplasma* infections, syndromic management and STI surveillance (2015-date).
- Co-ordinator for the 'Laboratory Aspects of HIV/STIs' module of the Masters of Medicine (HIV, STI and Sexual Health), University of Sydney (2015-2019)
- Established the University of Sydney-University of Washington 3-Day Short Course in HIV and STIs that ran successfully for three consecutive years until the COVID-19 pandemic occurred (2017-2019)
- Designed an annual integrated seminar for medical students using case studies to address clinical and microbiological aspects of STIs, including antimicrobial resistance (2020 to date)

## PhD and MSc SUPERVISIONS

### 1. PhD supervisions

- Co-Supervisor for PhD thesis of Habib Taouk, Curtin University (2025 to date) entitled “Achieving virtual elimination: what does it mean for those left behind in the Australian HIV response?”
- Primary Supervisor for PhD thesis of Dr. Catriona Ooi, University of Sydney (2014-2024) entitled “Services in Western Sydney for men who have sex with men who attend sex on premises venues.” Completed and candidate awarded her PhD degree in 2024.
- Primary Supervisor for PhD thesis of Dr. Cynthia Firnhaber, University of the Witwatersrand, South Africa (2011-2014) entitled “Validation of implementation of cervical cancer screening applications in HIV sero-positive women”. Transferred supervision in 2014 on move to Australia - candidate did not complete due to personal reasons.

### 2. MPhil supervisions

- Co-supervisor for MPhil thesis of Mr. Ashley Ubrihien, Macquarie University, Sydney, Australia (2016-2023) entitled “Access barriers preventing young Aboriginal People in Western Sydney using local Sexual Health services”.
- Supervisor for MMed MPhil thesis of Dr. L. Chandra, University of Sydney, Australia (2017-2018) entitled “The prevalence of bacterial STIs at various sites of infection among asymptomatic men-who-have-sex-with-men attending the clinic service at Western Sydney Sexual Health Centre”.
- Supervisor for MMed MPhil thesis of Dr. G. Warnares, University of Sydney, Australia (2016-2018) entitled “Prevalence of HIV-STI among women working in entertainment venues (parlours, karaokes, bars, clubs) in Jayapura, Papua – Indonesia”.

### 3. MSc supervisions

- Supervisor for MSc thesis of Ms. P. Magooa, University of the Witwatersrand, South Africa (2008-2010) entitled “Detection and molecular epidemiology of ciprofloxacin-resistant *Neisseria gonorrhoeae* using a real-time polymerase chain reaction”
- Supervisor for MSc summer project of Ms. C. Jones, London School of Hygiene and Tropical Medicine (2009) entitled “Comparison between cervicovaginal lavages and vaginal tampons for the detection of human papillomavirus DNA in genital secretions”
- Supervisor for MSc summer project of Ms. E. van Eijk, London School of Hygiene and Tropical Medicine (2010) entitled “Molecular detection of emergent extended-spectrum cephalosporin resistance among *Neisseria gonorrhoeae* isolates in South Africa”
- Supervisor for MSc summer project of Ms. M. Mosavie, London School of Hygiene and Tropical Medicine (2010) entitled “Antimicrobial susceptibility and molecular typing of

*Neisseria gonorrhoeae* isolates from men with urethral discharge in Alexandra Township, South Africa”

- Supervisor for MSc summer project of Ms. L. Luke, London School of Hygiene and Tropical Medicine (2011) entitled “*Ureaplasma* infections among men attending a clinic for sexually transmitted infections in south Africa: prevalence and associations with patients’ characteristics, symptoms and clinical signs”

## **PhD and MSc EXAMINER APPOINTMENTS**

### **1. PhD examiner appointments**

- Evaluation of Confirmation Document for the PhD research programme of Cameron Buckley, University of Queensland, Australia entitled “Factors that influence *Neisseria gonorrhoeae* antimicrobial resistance and transmission in Australia” (2017 and 2018)
- External examiner for PhD thesis of Phillip Read, University of New South Wales, Australia entitled “Clinical and epidemiological aspects of syphilis” (2016)
- External examiner for PhD thesis of Anna Yeung, University of Melbourne, Australia entitled “The acceptability and feasibility of a chlamydia testing intervention in Australian general practice” (2015)
- External examiner for PhD thesis of Ms. Sangeeta Kulkarni, University of Pune, India entitled “Quinolone resistance mutations of *Neisseria gonorrhoeae* in India” (2013)
- External examiner for PhD thesis of Mr. Namraj Goire, University of Queensland, Australia entitled “Molecular characterization and detection of gonococcal antimicrobial resistance” (2012)
- External examiner for PhD thesis of Ms. Zizipho Mbulawa, University of Cape Town, South Africa entitled “A study of genital human papillomavirus (HPV) infection and antibody response in heterosexually active South African couples” (2011)
- External examiner for PhD thesis of Ms. Sharlene Govender, University of Stellenbosch, South Africa entitled “Epidemiology, antibiotic resistance and gene transfer of *Mycoplasma* spp. and *Ureaplasma* spp.” (2010)

### **2. MSc examiner appointments**

- External examiner for the MSc thesis of Mr. Mathys Redelinghuys, University of Pretoria entitled “Association between genital mycoplasmas and bacterial vaginosis in pregnant women with or without genital symptoms” (2013)
- Internal Examiner for the MSc thesis of Ms. Ewalde Cutler, University of the Witwatersrand entitled “The association between the Prevalence of Human Papillomavirus, Male Circumcision and the Foreskin” (2012)



- External examiner for MSc thesis of Ms. Anna Salimo, University of Cape Town, South Africa entitled “An in depth study of HPV diversity in South African women infected with HIV” (2010)
- Internal examiner for MSc thesis of Mr. Nivashan Govender, University of the Witwatersrand, South Africa (2009) entitled “Molecular epidemiology and mechanism of resistance of invasive quinolone-resistant South African isolates of *Salmonella enterica*, 2004-06” (2009)
- External examiner for MSc thesis of Mr. Frans Radebe, University of the Witwatersrand entitled “Asymptomatic sexually transmitted diseases in Southern Africa” (2001)

## RESEARCH EXPERIENCE

### 1. Clinical trials

- A multicentre randomised controlled trial evaluating the efficacy of the four-component meningococcal B vaccine, 4CMenB (Bexsero®), in the prevention of *Neisseria gonorrhoeae* infection in gay and bisexual men.
- A randomized controlled trial of daily antimicrobial mouthwash to reduce pharyngeal gonorrhoea among men who have sex with men
- Use of molecular resistance assays to provide alternative oral treatment strategies for gonorrhoea in Indigenous and other high-risk populations; a randomised cluster trial
- A randomized controlled trial (of azithromycin versus doxycycline for the treatment of rectal chlamydia infection in men who have sex with men
- Impact of the rapid expansion of pre-exposure prophylaxis (PrEP) on HIV incidence, in a setting with high HIV testing and antiretroviral treatment coverage, to achieve the virtual elimination of HIV transmission by 2020: a NSW HIV Strategy implementation project.
- Phase III, randomised, double-blind, multicentre, parallel-group, non-inferiority study evaluating the efficacy, safety, and tolerability of dolutegravir plus lamivudine compared to dolutegravir plus tenofovir/emtricitabine in HIV-1 infected treatment-naïve adult (GEMINI-1)
- Randomised double blind-placebo controlled clinical trial of the effect on ulcer healing, and HIV shedding from sores, achieved through adding acyclovir to conventional syndromic management of genital ulcers in South African men

### 2. Community-based research

- STI/HIV and sexual health survey among Sydney Asian men who have sex with men
- Sexual health of men who have sex with men (MSM) attending a sex-on-premises venue in western Sydney

- Community roll-out of large-scale male circumcision in Orange Farm, South Africa, impact on HIV transmission at the community level and testing for biomarkers pre- and post-intervention
- Outreach HIV VCT testing and STI screening using mobile clinics among men and women in informal settlements in South Africa
- Assessment of new test to improve diagnosis of early HIV infection in South African miners using testing of B cell lysates (Plasmacut<sup>R</sup> test)

### 3. Clinic-based research

- Clinical, epidemiological and microbiological aspects of gonorrhoea, syphilis and trichomoniasis, as well as genital discharge and genital ulceration syndromes
- Assessment of HIV and syphilis screening of pregnant women in antenatal clinics
- Validation of cervical cancer screening methods

### 4. Laboratory-based research

- Typing of STI pathogens including human papillomavirus (genotyping), *Neisseria gonorrhoeae* (NG-MAST, auxotyping, serotyping, plasmid typing, ribotyping and DNA restriction fragment typing), *Treponema pallidum* (genotyping)
- Antimicrobial susceptibility studies on *Neisseria gonorrhoeae*, including conventional MIC determinations and establishment of molecular screening tests for PPNG plasmid types, TRNG plasmid types, *gyrA/parC* mutations, mosaic *penA* genes and other *penA* mutations
- Molecular detection of macrolide resistance in *Treponema pallidum* and acyclovir resistance in herpes simplex virus
- Evaluation of the rapid tests for diagnosis of syphilis (single treponemal antibody tests, dual syphilis tests, dual HIV and treponemal antibody tests) and identification of *Neisseria gonorrhoeae* (Rapid NH system)
- Comparison of CareHPV assay and the hybrid capture 2 assay for the detection of high-risk HPV types
- Development of an ELISA-based method, using monoclonal Abs against *H. ducreyi* heat shock proteins, for the detection of *H. ducreyi* in resource poor settings
- Whole genome analysis of *Chlamydia trachomatis* as a means to better understand inter-strain heterogeneity and phylogenetic relationships
- Studies on the molecular pathogenesis of chancroid which focused on characterisation of putative attachment factor (OapA), zinc binding protein (ZnuA) and cytolethal distending toxin complex (CdtABC), with training in the temperature-dependent rabbit model for experimental infection with *Haemophilus ducreyi*

## 5. Qualitative research

- Men's focus group and individual questionnaire study on access to healthcare and health-care seeking behaviour among men in South Africa
- Focus group assessing adolescents' knowledge, attitudes and practices around HIV-STI prevention
- Surveys on provider knowledge around STIs, in particular genital herpes

## 6. Non-STI/HIV/Hepatitis research

- Evaluation of antibiotics to treat community-acquired UTIs in South Africa
- Clinical trial of fosfomycin versus trimethoprim for uncomplicated UTIs in the UK
- Bacterial Meningitis in the North-East Thames Region: a clinical and laboratory study utilizing DNA typing methods in use for *Neisseria meningitidis*, and outer membrane protein analysis of *Haemophilus influenzae*
- Efficacy trial of an inhibitor of influenza virus A/B neuraminidase GR121167 (Glaxo) in a medical student hostel

## AWARDED RESEARCH GRANTS

- Wellcome Trust Research Training Fellowship in Clinical Tropical Medicine for £165,543 (Trainee) (1996)
- "The establishment of a diagnostic test for the early detection of the causative organism of syphilis and chancroid" funded by the Guy's and St. Thomas' Charitable Foundation for £13,000 (Co-Applicant) (2004)
- "Impact of episodic acyclovir therapy on ulcer duration and HIV shedding from genital ulcers among men in South Africa". Grant collaboration between STIRC (NICD), Centers for Disease Control and Prevention and LSHTM. Funded through the Centers for Disease Control and Prevention for \$250,000 (Co-Principal Investigator) (2003 to 2006)
- "Expansion of periodic presumptive treatment of STIs to three new mining communities". Funding for this study was provided by an Equity bilateral grant agreement through USAID for \$500,000 (Principal Investigator) (2003- 2006)
- "Introduction of VCT to marginalized communities and women at high risk around mines in South Africa". Funding for this study is provided by an Equity bilateral grant agreement through USAID for \$585,000 (Principal Investigator) (2005 – 2006)
- Enhancing syndromic management of sexually transmitted diseases (STIs) in cross border and high transit sites of Botswana, Lesotho, Namibia and

Swaziland. STI Reference Centre received £134,750 of this £1,800,000 awarded to the Health Systems Trust by the UK Government's Department for International Development (2004 to 2006)

- National Microbiological Syndromic Management for Sexually Transmitted Infections in South Africa. Awarded \$510,000 for 2006/07 through PEPFAR funding and NICD:CDC collaborative agreement (Principal Investigator) (2006 to 2007).
- National Clinical Syndromic Management for Sexually Transmitted Infections in South Africa. Awarded \$137,500 for 2006/07 through PEPFAR funding and NICD:CDC collaborative agreement (Principal Investigator) (2006 to 2007).
- "Initiating STD screening as part of routine HIV outpatient clinical care". Collaborative study between STIRC (NICD) and the Epidemiology and Surveillance Branch, Division of STD Prevention (DSTDP), CDC. Funding for this study is provided through PEPFAR (\$210,000 in 2006 plus \$120,244 in 2008) (Principal Investigator) (2006 to 2009)
- "Evaluation of maternal syphilis and HIV screening and treatment in Government-run antenatal clinic settings" Collaborative study between STIRC (NICD) and the Epidemiology and Surveillance Branch, Division of STD Prevention (DSTDP), CDC. Funding for this study is provided through PEPFAR (\$84,240) (In-country Principal Investigator with CDC PI lead) (2006 to 2007)
- "Evaluation of sexually transmitted infection (STI) clinical services in Gauteng Province, South Africa: knowledge, attitudes and practices among health care providers, and capacity, resources and barriers among facilities" Collaborative study between STIRC (NICD) and the Epidemiology and Surveillance Branch, Division of STD Prevention (DSTDP), CDC. Funding provided through PEPFAR (\$69,813 in 2006 plus \$259,067 in 2007) (In-country Principal Investigator with CDC PI lead) (2006 to 2010)
- "The Detection of HIV-specific T and B cell immunity in highly exposed HIV seronegative individuals". Collaborative study between STIRC (NICD), the HIV/AIDS Immunology Unit and Plasmacut. Funding provided through the Plasmacut, Norway (Euros 115,000) (Co-Principal Investigator) (2007-2008)
- "Detection of markers of exposure and possible protection in women at high risk of HIV-1 infection". Collaborative study between STIRC and the HIV/AIDS Immunology Unit of the NICD. Funding provided through the Poliomyelitis Research Foundation (ZAR 297,750) (Co-Principal Investigator) (2007-2010)
- "The Orange Farm Part 2 study: a community study of male circumcision". Collaborative study between STIRC (NICD) and the Paris-Ile-de-France-Ouest Medical School, University of Versailles. Funding provided through the ANRS, France (Euros 3,035,021) (In-country Co-Principal Investigator responsible for laboratory component) (2007 to 2010)
- "Focus group assessing adolescents' knowledge, attitudes and practices around HIV-STI prevention and development of an HIV-STI prevention animated video for youth". Collaborative study between STIRC (NICD) and the Epidemiology and Surveillance Branch, Division of STD Prevention (DSTDP), CDC. Funding for this study is provided through PEPFAR (\$185,081 in 2008) (In-country Principal Investigator with CDC PI lead) (2008 to 2010)

- “A microbiological study of community acquired urinary tract infection: relative prevalence and antimicrobial susceptibility of pathogens”. Funding for this study provided by Merck Serono South Africa (ZAR 266,918) (Principal Investigator) (2010-2011)
- “To obtain more and better quality regionally-derived data on antimicrobial resistance in *Neisseria gonorrhoeae* and to expand geographical coverage to include additional countries in Africa”. Funding from the World Health Organisation (\$37,380) (Principal Investigator) (2010-2011)
- “Aetiological sentinel surveillance for common STI syndromes, and determination of important sexually transmitted co-infections, among patients attending public health care facilities in South Africa”. Funding from the Global Disease Detection Programme (\$297,706, year 1) and PEPFAR funding through an NHLS-CDC co-operative agreement (\$687,293, year 2) (Principal Investigator) (2011-2015)
- “Factors affecting HIV susceptibility in the adolescent genital tract”. Funding from the European and Developing Countries Clinical Trial Partnership (Euros 1,720,651 for the consortium over 2 years) (Co-Applicant, Principal Investigator Jo-Ann Passmore) (2012-2014)
- “Genital Tract Inflammation test (GIFT)”. Funding from the Strategic Health Innovation Partnerships programme of the South African Medical Research Council (ZAR 3,300,000 for the consortium over 3 years) (Co-Investigator, Principal Investigator Jo-Ann Passmore) (2013-2016)
- “Diversity of viral quasispecies and HIV-1 drug resistance mutations in treated patients with low level viraemia”. Funded by the NSW Public Health Pathogen Genomics Consortium (AUD 13,000 over 1 year) (Co-investigator, Principal Investigator Shailendra Sawleshwarkar) (2015-2016)
- “Building institutional capacity to strengthen sexual health services in the SE Asia region”. Funded by the Australian Department of Foreign Affairs and Trade to host 15 participants from Indonesia, Cambodia and Timor-Leste in Round 17 of the Australia Awards (AUD 158,138 over 1 year) (Co-applicant, Lead applicant Shailendra Sawleshwarkar) (2017-2018)
- “Building institutional capacity to strengthen sexual health services in the Pacific region”. Funded by the Australian Department of Foreign Affairs and Trade to host 15 participants from PNG, Solomon Islands and Fiji in Round 17 of the Australia Awards (AUD 154,838 over 1 year) (Co-applicant, Lead applicant Shailendra Sawleshwarkar) (2017-2018)
- “Use of molecular resistance assays to provide alternative oral treatment strategies for gonorrhoea in Indigenous and other high-risk populations; a randomised cluster trial”. Funding from the Australian National Health and Medical Research Council (AUD 828,671) (Chief Investigator H, CI-A David Whiley) (2017-2021).
- “A randomized controlled trial of daily antimicrobial mouthwash to reduce pharyngeal gonorrhoea among men who have sex with men”. Funding from the Australian National

Health and Medical Research Council (AUD 376,730) (Chief Investigator F, CI-A Eric Chow) (2017-2019)

- “A randomized controlled trial (RCT) of azithromycin versus doxycycline for the treatment of rectal chlamydia infection in men who have sex with men”. Funding from the Australian National Health and Medical Research Council (AUD 797,905.60) (Associate Investigator, CI-A Jane Hocking) (2017-2019)
- “A GIFT (Genital Inflammation Test) for HIV prevention”. Funding from the South African Medical Research Council to support GIFT device validation and pilot rollout studies (ZAR 5,677,665) (Co-Investigator, Co-Principal Investigators Jo-Ann Passmore and Lindi Masson) (2017-2020)
- NSW Health Prevention Research Support Program (PRSP) Round 5. Funding from the NSW Ministry of Health (AUD 2,000,000) (Co-applicant with V. Sintchenko, T. Sorrell, L. Gilbert, J. Iredell, D. Dwyer, S. Chen, C. Webb, M. Douglas, W. Meyer, M. O’Sullivan, D. Lewis, J. Kok) (2017-2021)
- “Modelling response strategies to inform future public health interventions against emergence and spread of extensively drug resistant gonorrhoea”. Triple I seed grant from University of New South Wales (AUD 74,453) (co-PI, Principal PI David Regan) (2018-2019)
- “Modelling the impact of strategies to control gonorrhoea and minimise the threat of antimicrobial resistance in remote Indigenous and other high risk populations”. Funding from the Australian National Health and Medical Research Council (AUD 467,078.80) (Chief Investigator H, CI-A David Regan) (2018-2020)
- “Antibiotic treatment of male partners to reduce recurrence of bacterial vaginosis in women: a randomised double-blind controlled trial”. Funding from the Australian National Health and Medical Research Council (AUD 636,673.60) (Chief Investigator E, CI-A Catriona Bradshaw) (2018-2020)
- “ARC Research Hub to Combat Antimicrobial Resistance”. Funding from the Industrial Transformation Research Hubs scheme of the Australian Research Council (AUD 4,999,540) (Researcher [Other Organizations], Lead Investigator, Rebecca Guy) (2019-2024)
- “Defining pathways of epithelial spread of Herpes simplex virus after genital infection” Funding from the Australian National Health and Medical Research Council (AUD 863,035.40) (Associate Investigator, CI-A Anthony Cunningham) (2019-2023)
- “A multicentre randomised controlled trial evaluating the efficacy of the meningococcal B vaccine, 4CMenB (Bexsero), against *Neisseria gonorrhoeae* infection in gay and bisexual men”. Funding from the Australian National Health and Medical Research Council (AUD 2,735,991) (Chief Investigator E, CI-A Kate Seib) (2020-2023)
- “The development of novel pharmacokinetic techniques to optimise treatment and reduce antimicrobial resistance for sexually transmitted infections (STIs)”. Funding from the Australian National Health and Medical Research Council (AUD 1,469,609) (Associate Investigator, CI-A Fabian Kong) (2020-2022)

- “Can mass drug administration control endemic sexually transmitted infections and their health consequences? A proof-of-concept community trial”. Funding from the Australian National Health and Medical Research Council (AUD 2,148,887) (Associate Investigator, CI-A Lucia Romani) (2022-2026)
- NSW Health Prevention Research Support Program (PRSP) Round 6. Funding from the NSW Ministry of Health (AUD 1,800,000) (Co-applicant with V. Sintchenko (lead), S. Bag, S. Chen, D. Lewis, M. Douglas, D. Dwyer, T. Golubchik, J. Iredell, J. Kok, M O’Sullivan, R Rockett, T. Sorrell, K Tannous, M Watts and C. Webb) (2022-2026)
- “Implementation science to guide the effective introduction of long-acting injectable HIV pre-exposure prophylaxis (PrEP) in Australia”. Partnership grant with funding from the Australian National Health and Medical Research Council (AUD 1,499,000) (Chief Investigator I, CI-A Ben Bavinton)

## PUBLICATIONS IN PEER-REVIEWED JOURNALS

1. Steer HW, **Lewis DA**. Peritoneal cell responses in acute gastrointestinal inflammation. *J. Pathol.* 1983;**140**:237-253
2. **Lewis DA**, Brook G. Erythema multiforme as a presentation of human immunodeficiency virus seroconversion illness. *Int. J. STD and AIDS* 1992;**3**:56-57
3. Berlyne GS, **Lewis DA**, Madge SJ, Weir WRC. Multiple pathology in an HIV positive man. *Int. J. STD and AIDS* 1995;**6**:127-129
4. **Lewis DA**, Pollock LM, Randell J, Wilson P, Kopelman PG. Acute gonococcal arthritis: An atypical host and pathogen combination. *J. Clin. Pathol.* 1995;**48**:86-88
5. **Lewis DA**, Ison CA, Livermore DM, Chen HY, Hooi AY, Wisdom AR. A one year survey of *Neisseria gonorrhoeae* isolated from patients attending an East London Genitourinary Medicine Clinic: antibiotic susceptibility patterns and patients' characteristics. *Genitourin. Med.* 1995;**71**:13-17
6. **Lewis DA**, CN Amerasinghe, SM Murphy. Successful treatment of Behçet's syndrome in an African female patient with thalidomide. *Int. J. STD and AIDS* 1996;**7**:518-520
7. **Lewis DA**. Behçet's Syndrome: a review for the genitourinary medicine physician. *Int. J. STD and AIDS* 1996;**7**:176-183
8. **Lewis DA**, Ison CA, Forster GE, Goh BT. Tetracycline resistant *Neisseria gonorrhoeae*: characteristics of patients and isolates at a London Genitourinary Medicine Clinic. *Sex. Trans. Dis.* 1996;**23**:378-383

9. **Lewis DA**, Al-Adnani MS, Murphy SM. Altered seminal ejaculate consistency due to schistosomiasis. *Br. J. Urol.* 1996;**78**:956-957
10. **Lewis DA**, Habgood L, White R, Barker K, Murphy SM. Managing vaginal trichomoniasis resistant to high-dose metronidazole therapy. *Int. J. STD and AIDS* 1997;**8**:780-784
11. Minassian MA, **Lewis DA**, Chattopadhyay D, Bovill B, Duckworth GJ, Williams JD. A comparison between single-dose fosfomycin trometamol (Monuril) and a 5-day course of trimethoprim in the treatment of uncomplicated lower urinary tract infection in women. *Int. J. Antimicrob. Agents* 1998;**10**:39-47
12. **Lewis DA**. The use of experimental animal and human models in the study of chancroid pathogenesis. *Int. J. STD and AIDS* 1999;**10**:71-79
13. **Lewis DA**, Bond M, Butt KD, Smith CP, Shafi MS, Murphy SM. A one year survey of gonococcal infection seen in the genitourinary medicine department of a London district general hospital. *Int. J. STD and AIDS* 1999;**10**:588-594
14. **Lewis DA**, Klesney-Tait J, Lumbley SR, Ward CK, Latimer JL, Ison CA, Hansen EJ. Identification of the *znuA*-encoded periplasmic zinc transport protein of *Haemophilus ducreyi*. *Infect. Immun.* 1999;**67**:5060-5068
15. **Lewis DA**. Chancroid: from clinical practice to basic science. *AIDS patient care and STDs* 2000;**14**:19-36
16. **Lewis DA**. Diagnostic tests for chancroid. *Sex. Transm. Inf.* 2000;**76**:137-141
17. **Lewis DA**, Deng K, Stevens MK, Latimer JL, Ward CK, Blick R, Lumbley SR, Ison CA, Hansen EJ. Characterization of *Haemophilus ducreyi* *cdtA*, *cdtB* and *cdtC* mutants in *in vitro* and *in vivo* systems. *Infect. Immun.* 2001;**69**:5626-5634
18. Deng K, Latimer JL, **Lewis DA**, Hansen EJ. Investigation of the interaction among the components of the cytolethal distending toxin of *Haemophilus ducreyi*. *Biochem. Biophys. Res. Commun.* 2001;**285**:609-615
19. **Lewis DA**. Chancroid: clinical manifestations, diagnosis and management. *Sex. Transm. Inf.* 2003;**79**:68-71
20. Kulkarni K, **Lewis DA**, Ison CA. Expression of the cytolethal distending toxin in a geographically diverse collection of *Haemophilus ducreyi* clinical isolates. *Sex. Trans. Inf.* 2003;**79**:294-297
21. Passos MRL, Barreto NA, Varella RQ, Rodrigues GHS, **Lewis DA**. Penile myiasis: a case report. *Sex. Transm. Inf.* 2004;**80**:183-184
22. **Lewis DA**. Improving men's sexual health: a challenge for today. *Sex. Transm. Inf.* 2004;**80**:423-424



23. **Lewis DA**, McDonald A, Thompson G, Bingham JS. The 374 clinic: an outreach sexual health clinic for young men. *Sex. Transm. Inf.* 2004;**80**:480-483
24. Annan NT, **Lewis DA**. The treatment of chancroid in resource poor countries. *Expert Rev. Anti Infect. Ther.* 2005;**3**:295-306
25. Cortes N, Afzali B, Maclean D, Goldsmith D, O'Sullivan H, Bingham J, **Lewis DA**, MacMahon E, Tong CYW, Koffman G. Transmission of syphilis by solid organ transplantation. *Am. J. Transplantation* 2006;**6**:2497-9
26. **Lewis DA**, Young H. Syphilis. *Sex. Transm. Infect.* 2006;**82**:Suppl 4:iv13-iv15
27. **Lewis DA**, Ison CA. Chancroid. *Sex. Transm. Infect.* 2006;**82**:Suppl 4:iv19-iv20
28. **Lewis DA**. Antibiotic resistant gonococci: past, present and future. *South Afr. Med. J.* 2007;**97**:1146-1150
29. **Lewis DA**, Latif AS, Ndowa F. The Global Strategy for the Prevention and Control of Sexually Transmitted Infections: time for action. *Sex. Transm. Infect.* 2007;**83**:508-509
30. Black V, Magooa P, Radebe F, Myers M, Pillay C, **Lewis DA**. The detection of urethritis among patients with the male urethritis syndrome, genital ulcer syndrome and HIV VCT clients: should South Africa's syndromic management approach be revised? *Sex. Transm. Inf.* 2008;**84**:254-258
31. **Lewis DA**, Scott L, Slabbert M, Mhlongo S, van Zijl A, Sello M, du Plessis N, Radebe F, Wasserman E. Escalation in the relative prevalence of ciprofloxacin resistant gonorrhoea among men with urethral discharge in two South African cities – implications for HIV transmission. *Sex. Transm. Infect.* 2008;**84**:352-355
32. **Lewis DA**, Pillay C, Mohlamonyane O, Vezi A, Mbabela S, Mzaidume Y, Radebe F. The burden of asymptomatic sexually transmitted infections among men in Carletonville, South Africa – implications for syndromic management. *Sex. Transm. Infect.* 2008;**84**:371-376
33. Johnson LF, **Lewis DA**. The effect of genital tract infections on HIV-1 shedding in the genital tract: a systematic review and meta-analysis. *Sex. Transm. Dis.* 2008;**35**:946-959
34. Ross JDC, Garcia PJ, Zenilman J, **Lewis DA**, Chan R, Poder A. Summary of proceedings of the IUSTI Global Challenges Symposium (ISSTD 2007/10<sup>th</sup> IUSTI World Congress). *Int. J. STD AIDS* 2009;**20**:130-134
35. Odinsen O, Parker D, Radebe F, **Lewis DA**. Early detection of HIV-1 specific B lymphocyte derived antibodies in a high risk population. *Clin. Vaccine Immunol.* 2009;**16**:1060-1065
36. Rigsby P, Ison C, Brierley M, Ballard R, Hagedorn H-J, **Lewis DA**, Notermans DW, Riis J, Robertson P, Seppälä IJT, Rijpkema S. Evaluation of two human plasma pools as

- candidate International Standard Preparations for syphilitic antibodies. *Biologicals* 2009;**37**:245-251
37. **Lewis DA**, Marumo E. Revision of the National Guideline for First-Line Comprehensive Management and Control of Sexually Transmitted Infections: What's New and Why? *South Afr. J. Epid. Infect.* 2009;**24**:6-9 and reprinted in *South Afr. Fam. Pract.* 2010;**52**:20-24
38. **Lewis DA**. The demise of ciprofloxacin - another class of anti-gonococcal antibiotics bites the dust. *S. Afr. J. Epid. Infect.* 2009;**24**:3-4
39. Paz-Bailey G, Sternberg M, **Lewis DA**, Cutler E, Vos M, Ballard R, Puren A. Comparison of lavage and swabs for the collection of genital ulcer specimens to measure HIV RNA shedding. *J. Clin. Virol.* 2009;**46**:165-168
40. Paz Bailey G, Sternberg M, Puren AJ, Markowitz LE, Ballard R, Delany S, Hawkes S, Nwanyanwu O, Ryan C, **Lewis DA**. Improvement in healing and reduction on HIV shedding with episodic acyclovir among men as part of syndromic management; a randomized controlled trial. *J. Infect. Dis.* 2009;**200**:1039-1049
41. Tapsall JW, Ndowa F, **Lewis DA**, Unemo M. Meeting the public health challenge of multi-drug and extensively-drug resistant *Neisseria gonorrhoeae*. *Expert Rev. Anti Infect. Ther.* 2009;**7**:821-834
42. Firnhaber CS, Le HV, Pettifor A, Schulze D, Michelow P, Sanne IM, **Lewis DA**, Williamson A, Allan B, Williams S, Rinas A, Levin S, Smith JS. Association between cervical dysplasia and human papillomavirus in HIV seropositive women from Johannesburg, South Africa. *Cancer Causes Control* 2010;**21**:433-443
43. Paz Bailey G, Sternberg M, **Lewis DA**, Puren A. Acute HIV infections among men with genital ulcer disease in South Africa. *J. Infect. Dis.* 2010;**201**:1811-1815
44. Paz-Bailey G, Sternberg M, Puren AJ, Steele L, **Lewis DA**. Determinants of HIV type 1 shedding from genital ulcers among men in South Africa. *Clin. Infect. Dis.* 2010;**50**:1060-1067
45. Müller EE, Chirwa T, **Lewis DA**. Human papillomavirus (HPV) infection in heterosexual South African men attending sexual health services: associations between HPV and HIV serostatus. *Sex. Transm. Infect.* 2010;**86**:175-180
46. Mhlongo SP, Magooa P, Müller EE, Nel N, Radebe F, Wasserman E, **Lewis DA**. Etiology and STI/HIV co-infections among patients with urethral and vaginal discharge syndromes in South Africa. *Sex. Transm. Dis.* 2010;**37**:566-570
47. **Lewis DA**. Modern management of genital ulcer disease – frappez fort et frappez vite. *Sex. Transm. Dis.* 2010;**37**:494-496

48. **Lewis DA.** The gonococcus fights back – is this time a knock out? *Sex. Transm. Infect.* 2010;**86**:415-421
49. Lissouba P, Taljaard D, Rech D, Doyle S, Shabangu D, Nhlapo C, Darko-Otchere J, Mashigo T, Tarnaud C, **Lewis D**, Scott B, Auvert B. A model for the roll-out of comprehensive adult male circumcision services in African low income settings of high HIV incidence: the ARNS 12126 Bophelo Pele Project. *PLoS Med.* 2010;**7**(7):e1000309.
50. Chisholm S, Mouton JW, **Lewis DA**, Nichols T, Ison CA, Livermore DM. Cephalosporin MIC-creep among gonococci: time for a pharmacodynamic re-think? *J. Antimicrob. Chemother.* 2010;**65**:2141-2148
51. Venter JME, Müller EE, Maseko VD, **Lewis DA.** Is the new variant *Chlamydia trachomatis* present in South Africa? *South Afr. J. Epidemiol. Infect.* 2011;**26**:36-37
52. Fayemiwo S, Müller EE, Gumede L, **Lewis DA.** Plasmid-mediated penicillin and tetracycline resistance among *Neisseria gonorrhoeae* isolates in South Africa: prevalence, detection and typing using a novel molecular assay. *Sex. Transm. Dis.* 2011;**38**:329-333
53. Damelin LH, Paximadis M, Mavri-Damelin D, Birkhead M, **Lewis DA**, Tiemessen CT. Identification of predominant culturable vaginal *Lactobacillus* species and associated bacteriophages from women with and without vaginal discharge syndrome in South Africa. *J. Med. Microbiol.* 2011;**60**:180-183
54. Firnhaber C, Sello M, Maskew M, Williams S, Schulze D, Williamson A, Allan B, **Lewis D.** Human papillomavirus types in HIV seropositive men with genital warts in Johannesburg, South Africa. *Int. J. STD and AIDS* 2011;**22**:107-109
55. Leichliter JS, Paz Bailey G, Friedman A, Habel MA, Vezi A, Sello M, Farirai T, **Lewis DA.** ‘Clinics aren’t meant for men’: sexual health access and seeking behaviours among men in Gauteng province, South Africa. *SAHARA J.* 2011;**8**:82-88
56. Leichliter JS, **Lewis DA**, Sternberg M, Habel MA, Paz-Bailey G. Health care seeking among men with genital ulcer disease in South Africa: correlates and relationship to HIV-1 and HSV-2 detection and shedding. *Sex. Transm. Dis.* 2011;**38**:865-870
57. Müller EM, Fayemiwo SA, **Lewis DA.** Characterization of a novel beta-lactamase-producing plasmid in *Neisseria gonorrhoeae*: sequence analysis and molecular typing of host gonococci. *J. Antimicrob. Chemother.* 2011;**66**:1514-1517
58. **Lewis DA**, Lukehart SA. Antimicrobial resistance in *Neisseria gonorrhoeae* and *Treponema pallidum*: evolution, therapeutic challenges and the need to strengthen global surveillance. *Sex. Transm. Infect.* 2011;**87**:ii39-ii43
59. **Lewis DA.** Antimicrobial resistant gonorrhoea in Africa: an important threat to public health in need of a regionally-based gonococcal antimicrobial surveillance programme. *South Afr. J. Epi. Infect.* 2011;**26**:215-220

60. **Lewis DA.** Cefixime is first-line treatment for gonorrhoea in South Africa. *South Afr. J. Epidemiol. Infect.* 2011;**26**:103-104
61. Weiss HA, Paz-Bailey G, Phiri S, Gresenguet G, LeGoff J, Pepin J, **Lewis DA**, Belec L, Hoffman I, Miller WC, Mayaud P. Episodic therapy for genital herpes in sub-Saharan Africa: a pooled analysis from three randomized controlled trials. *PLoS ONE* 2011;**6**: e22601
62. Hong HA, Loubser AS, de Assis Rosa D, Naranbhai V, Carr W, Paximadis M, **Lewis DA**, Tiemessen CT, Gray CM. Killer-cell immunoglobulin-like receptor genotyping and HLS KIR-ligand identification by real-time PCR. *Tissue Antigens* 2011;**78**:185-194
63. **Lewis DA.** HIV/STI epidemiology, management and control in the IUSTI-Africa Region: focus on sub-Saharan Africa. *Sex. Transm. Infect.* 2011;**87**:ii10-ii13
64. Crowther-Gibson P, Govender N, **Lewis DA**, Bamford C, Brink A, von Gottberg, Klugman K, du Plessis M, Fali A, Harris B, Botha M. Human infections and antibiotic resistance. *South Afr. Med. J.* 2011;**101**:567-578
65. Bamford C, Brink A, Govender N, **Lewis DA**, Perovic O, Botha M, Harris B, Gelband H, Duse AG. Surveillance activities. *South Afr. Med. J.* 2011;**101**:579-582
66. Lissouba P, Taljaard D, Rech D, Dermaux-Msimang V, Legeai C, **Lewis D**, Singh B, Puren A, Auvert B. Adult male circumcision as an intervention against HIV: an operational study of uptake in a South African community (ANRS 12126). *BMC Infect. Dis.* 2011;**11**:253
67. Müller EM, Venter JME, Magooa MP, Morrison C, **Lewis DA**, Napierala-Mavedzenge S. Development of a rotor-gene real-time PCR assay for the detection and quantification of *Mycoplasma genitalium*. *J. Microbiol. Methods* 2011;**88**:311-315
68. Harris SR, Clarke IN, Seth-Smith HMB, Solomon AW, Cutcliffe LT, Marsh P, Skilton RJ, Holland MJ, Mabey D, Peeling R, **Lewis DA**, Spratt B, Unemo M, Persson K, Bjartling C, Brunham R, de Vries HJC, Morre S, Speksnijder A, Bébéar CM, Clerc C, Barbeyrac B, Parkhill J, Thomson NR. Whole-genome analysis of diverse *Chlamydia trachomatis* strains identifies phylogenetic relationships masked by current clinical typing. *Nature Genetics* 2012;**44**:413-419
69. Ross JDC, **Lewis DA.** Cephalosporin resistant *Neisseria gonorrhoeae*: time to consider gentamicin? *Sex. Transm. Infect.* 2012;**88**:6-8
70. **Lewis DA**, Chirwa T, Msimang V, Radebe F, Kamb M, Firnhaber C. Urethritis/cervicitis pathogen prevalence and associated risk factors among asymptomatic HIV-infected patients in South Africa. *Sex. Transm. Dis.* 2012;**39**:531-536
71. **Lewis DA.** Detection of acute HIV infections in STI patients: a window of opportunity for HIV prevention in South Africa? *South Afr. J. Epidemiol. Infect.* 2012;**27**:149-155

72. Müller EM, Paz-Bailey G, **Lewis DA**. Macrolide resistance testing and molecular subtyping of *Treponema pallidum* strains from southern Africa. Sex. Transm. Infect. 2012;**88**:470-474
73. **Lewis DA**, Müller EM, Steele L, Sternberg M, Radebe F, Lyall M, Ballard RC, Paz-Bailey G. Prevalence and association of genital ulcer and urethral pathogens in men presenting with genital ulcer syndrome to primary healthcare clinics in South Africa. Sex. Transm. Dis. 2012;**39**:880-885
74. **Lewis DA**, Sriruttan C, Coetzee J. Detection of multi-drug resistant gonorrhoea in the Gauteng Province. S. Afr. J. Epid. Infect. 2012;**27**:199-200
75. Firnhaber C, Mayisela N, Mao L, Williams S, Swarts A, Faesen M, Levin S, Michelow P, Omar T, Hudgens MG, Williamson A, Allan B, **Lewis DA**, Smith JS. Validation of cervical cancer screening methods in HIV positive women from Johannesburg, South Africa. PLoS One 2013;**8**(1):e53494.
76. **Lewis DA**, Sriruttan C, Müller EM, Golparian D, Gumede L, Fick D, de Wet J, Maseko V, Coetzee JJ, Unemo M. Phenotypic and genetic characterization of the first two cases of extended-spectrum cephalosporin resistant *Neisseria gonorrhoeae* infection in South Africa and association with cefixime treatment failure. J. Antimicrob. Chemother. 2013;**68**:1267-1270
77. Seth-Smith, HMB, Harris SR, Skilton RJ, Cutcliffe LT, Radebe FM, Golparian D, Shipitsyna E, Duy PT, O'Neill C, Parmar S, Pitt R, Baker S, Ison CA, Marsh P, Jalal H, **Lewis DA**, Unemo M, Clarke IN, Parkhill J, Thomson NR. Whole genome sequences of the fastidious bacterium *Chlamydia trachomatis* directly from clinical samples without culture. Genome Res. 2013;**23**:855-866
78. Magooa MP, Müller EE, Gumede L, **Lewis DA**. Determination of *Neisseria gonorrhoeae* susceptibility to ciprofloxacin in clinical specimens from men using a real-time polymerase chain reaction assay. Int. J. Antimicrob. Agents 2013;**42**:63-67
79. **Lewis DA**, Gumede LYE, van der Hoven L, de Gita GN, de Kock EJE, de Lange T, Maseko V, Kekana V, Smits F, Perovic O. Antimicrobial susceptibility of organisms causing community-acquired urinary tract infections in Gauteng Province, South Africa. S. Afr. Med. J. 2013;**103**:377-381
80. **Lewis DA**. Gonorrhoea resistance among men-who-have-sex-with-men: what's oral sex got to do with it? South Afr. J. Epidemiol. Infect. 2013;**28**:77
81. **Lewis DA**, Marsh K, Radebe F, Maseko V, Hughes G. Trends and associations of *Trichomonas vaginalis* infection in men and women with genital discharge syndromes in Johannesburg, South Africa. Sex. Transm. Infect. 2013;**89**:523-527
82. Müller EE, Magooa MP, **Lewis DA**. Genetic characterization of Herpes simplex virus type 2 *UL23* thymidine kinase in Johannesburg, South Africa. J. Antivir. Antiretrovir. 2013;**5**:080-084

83. Auvert B, Taljaard D, Rech D, Lissouba P, Singh B, Bouscaillou J, Peytavin G, Mahiane G, Sitta R, Puren A, **Lewis D**. Association of the ANRS-12126 male circumcision project with HIV levels among men in a South African township: evaluation of effectiveness using cross-sectional surveys. *PLoS Med.* 2013;**10**(9):e1001509
84. Dinh T-H, Kamb ML, Msimang V, Likibi M, Molebatsi T, Goldman T, **Lewis DA**. Integration of preventing mother-to-child transmission of HIV and syphilis testing and treatment in antenatal care services in the Northern Cape and Gauteng provinces, South Africa. *Sex. Transm. Dis.* 2013;**40**:846-851
85. **Lewis DA**, Hughes G. Professor Cathy Ison – her contribution to the science and practice of STI control. *Sex. Transm. Infect.* 2013;**80**:610-611
86. **Lewis DA**. The role of core groups in the emergence and dissemination of antimicrobial resistant *N. gonorrhoeae*. *Sex. Transm. Infect.* 2013;**89** Suppl 4:iv47-iv51
87. Unemo M, Dillon JR, **Lewis DA**. *Neisseria gonorrhoeae* is evolving into a “superbug” – what measures can be implemented to combat the emergence of multi-drug and extensively-drug resistant gonorrhoea in Latin America and globally? *J. Bras. Doenças Sex. Transm.* 2013;**25**:3-5
88. Ngou J, Magooa MP, Gilham C, Djigma F, Didelot M-N, Kelly H, Yonli A, Sawadogo B, **Lewis DA**, Delany-Moretlwe S, Mayaud P, Segondy M. Comparison of the *CareHPV* assay with the Hybrid Capture 2 assays for detection of high-risk HPV DNA in cervical samples from HIV-1-infected African women. *J. Clin. Microbiol.* 2013;**51**:4240-4242
89. **Lewis DA**. Global resistance to *Neisseria gonorrhoeae*: when theory becomes reality. *Curr. Opin. Infect. Dis.* 2014;**27**:62-67
90. Mitchell, HD, **Lewis DA**, Marsh K, Hughes G. Distribution and risk factors of *Trichomonas vaginalis* infection in England: An epidemiological study using electronic health records from sexually transmitted infection clinics. *Epid. Infect.* 2014;**142**:1678-1687
91. Vandepitte J, Hughes P, Bukusuba J, Matovu G, Bukenya J, Grosskurth H, **Lewis DA**. High prevalence of ciprofloxacin-resistant gonorrhoea among female sex workers in Kampala, Uganda. *Sex. Transm. Dis.* 2014;**41**:233-237
92. Olivier AJ, Masson L, Ronacher K, Walzl G, Coetzee D, **Lewis DA**, Williamson A, Passmore JS, Burgers WA. Distinct cytokine patterns in semen influence local HIV shedding and HIV target cell activation. *J. Infect. Dis.* 2014;**209**:1174-1184
93. **Lewis DA**. Epidemiology, clinical features, diagnosis and treatment of *Haemophilus ducreyi* – a disappearing pathogen? *Expert Rev. Anti-infect. Ther.* 2014;**12**:687-696
94. Peters RPH, Dubbink JH, van der Eem L, Verweij SP, Bos MLA, Ouburg S, **Lewis DA**, Struthers H, McIntyre JA, Morr  SA. Cross-sectional study of genital, rectal and pharyngeal

- chlamydia and gonorrhoea in women in rural South Africa. *Sex. Transm. Dis.* 2014;**41**:564-569
95. Hawkes S, **Lewis DA**. HPV vaccine strategies – equitable and effective? *Sex. Transm. Infect.* 2014;**90**:510-511
96. Takuva S, Mutsvangwa J, Machiha A, Mupambo AC, Maseko V, Cham F, Mungofa S, Mason P, **Lewis DA**. Aetiology and antimicrobial susceptibility of pathogens responsible for urethral discharge among men in Harare, Zimbabwe. *Sex. Transm. Dis.* 2014;**41**:713-717
97. O’Leary A, Jemmott III JB, Jemmott LS, Teitelman A, Heeren GA, Ngwane Z, Icard L, **Lewis DA**. Associations between psychosocial factors and incidence of sexually transmitted diseases among South African adolescents. *Sex. Transm. Dis.* 2015;**42**:135-139
98. Firnhaber CS, Mao L, Levin S, Faesen M, **Lewis DA**, Goeieman BJ, Swarts AJ, Rakhombe N, Michelow PM, Williams S, Smith JS. Evaluation of a cervicography-based program to quality assure visual inspection of the cervix in HIV infected women in Johannesburg, South Africa. *J. Low. Genit. Tract Dis.* 2015;**19**:7-11
99. Napierala Mavedzenge S, Muller EE, **Lewis DA**, Chipato T, C Morrison C, Weiss HA. *Mycoplasma genitalium* is associated with increased genital HIV-1 RNA in Zimbabwean women. *J. Infect. Dis.* 2015;**211**:1288-1298
100. Low N, Stroud K, **Lewis DA**, Cassell J. Mind your binomials: a guide to microbial nomenclature and spelling in *Sexually Transmitted Infections*. *Sex. Transm. Infect.* 2015;**91**:154-155
101. **Lewis DA**. Will targeting oro-pharyngeal gonorrhoea delay the further emergence of drug-resistant *Neisseria gonorrhoeae* strains? *Sex. Transm. Infect.* 2015;**91**:234-237
102. Couldwell DL, **Lewis DA**. *Mycoplasma genitalium* infection: current treatment options, therapeutic failure and resistance-associated mutations. *Infect. Drug Resist.* 2015;**8**:147-161
103. Jemmott III JB, Jemmott LS, O’Leary A, Ngwane Z, **Lewis DA**, Bellamy SL, Icard LD, Carty C, Heeren GA, Tyler JC, Makiwane MB, Teitelman A. HIV risk-reduction-intervention efficacy with South African adolescents over 54 months. *Health Psychol.* 2015;**34**:610-621
104. Masson L, Salkinder AL, Olivier AJ, McKinnon L, Gamielidien H, Mlisana K, Scriba T, **Lewis DA**, Little F, Jaspan H, Ronacher K, Denny L, Abdool Karim SS, Passmore JS. Relationship between female genital tract infections, mucosal IL-17 production and local Th17 cells. *Immunology* 2015;**146**:557-567

105. Rebe K, **Lewis D**, Myer L, De Swardt G, Struthers H, Kamkuemah M, McIntyre J. A cross-sectional analysis of gonococcal and chlamydial infections among men-who-have-sex-with-men in Cape Town, South Africa. *PLoS One* 2015;**10**(9):e0138315
106. Ooi CJ, **Lewis DA**. Updating the management of sexually transmitted infections. *Australian Prescriber* 2015;**38**:204-208
107. Ham DC, Hariri S, Kamb M, Mark J, Ilunga R, Forhan S, Likibi L, **Lewis DA**. Quality of sexually transmitted infection (STI) case management services in Gauteng Province, South Africa: an evaluation of health providers' knowledge, attitudes and practices. *Sex. Transm. Dis.* 2016;**43**:23-29
108. **Lewis DA**, Mitjà O. *Haemophilus ducreyi*: from sexually transmitted infection to skin ulcer pathogen. *Curr. Opin. Infect. Dis.* 2016;**29**:52-27
109. Wessels A, Bamford C, **Lewis D**, Martini M, Wainwright H. Syphilitic lymphadenitis clinically and histologically mimicking lymphogranuloma venereum. *S. Afr. Med. J.* 2016;**106**:465-467
110. Masson L, Arnold KB, Little F, Mlisana K, **Lewis DA**, Mkhize N, Gamiieldien H, Ngcapu S, Johnson L, Lauffenburger D, Abdool Karim Q, Abdool Karim SS, Passmore JS. Inflammatory cytokine biomarkers to identify women with asymptomatic sexually transmitted infections and bacterial vaginosis who are at high risk of HIV infection. *Sex. Transm. Infect.* 2016;**92**:186-193
111. Leichliter JS, **Lewis DA**, Paz-Bailey G. Correlates of bacterial ulcers and acute HSV-2 infection among men with genital ulcer disease in South Africa: age, recent sexual behaviours and HIV. *South. Afr. J. Infect. Dis.* 2016;**31**:61-65
112. Jean K, Puren A, Cutler E, Singh B, Bouscaillou J, Rain-Taljaard R, Taljaard D, Gouws E, Lissouba P, **Lewis DA**, Peytavin G, Auvert B. Level of viral suppression and the cascade of HIV care in a South African semi-urban setting in 2012. *AIDS* 2016;**30**:2107-2116
113. Müller EE, Rebe K, Chirwa TF, Struthers H, McIntyre J, **Lewis DA**. The prevalence of human papillomavirus infections and associated risk factors in men-who-have-sex-with-men in Cape Town, South Africa. *BMC Infectious Diseases* 2016;**16**:440
114. Lahra MM, Dillon JR, George CRR, **Lewis DA**, Wi TE, Whiley DM. From zero to zero in 100 years: gonococcal antimicrobial resistance. *Microbiology Australia* 2016; 173-176 <http://dx.doi.org/10.1071/MA16058>
115. Black V, Williams BG, Maseko V, Radebe F, Rees HV, **Lewis DA**. Field evaluation of Standard Diagnostics' Bioline HIV/Syphilis Duo Test among female sex workers in Johannesburg, South Africa. *Sex. Transm. Infect.* 2016;**92**:495-498
116. Goire N, Kundu R, Trembizki E, Buckley C, Hogan TR, **Lewis DA**, Branley JM, Whiley DM, Lahra, MM. Mixed gonococcal infections in a high-risk population, Sydney,



- Australia 2015: implications for antimicrobial resistance surveillance? *J. Antimicrob. Chemother.* 2017;**72**:407-409
117. Maraux B, Lissouba P, Rain-Taljaard R, Taljaard D, Bouscaillou J, **Lewis DA**, Puren A, Auvert B. Women's knowledge and perception of male circumcision before and after its roll-out in the South African township of Orange Farm from community-based cross-sectional surveys. *PLoS ONE* 2017;**12**(3):e0173595
118. **Lewis DA**. Antimicrobial resistance surveillance for *Neisseria gonorrhoeae* - what do we really need to know in order to guide public health interventions? *Sex. Transm. Dis.* 2017;**44**:202-204
119. Lau A, Kong F, Fairley CK, Donovan B, Chen M, Bradshaw C, Boyd M, Amin J, Timms P, Tabrizi S, Regan DG, **Lewis DA**, McNulty A, Hocking JS. Treatment efficacy of azithromycin 1g single dose versus doxycycline 100mg twice daily for 7 days for the treatment of rectal chlamydia among men who have sex with men - a double blind randomised controlled trial protocol. *BMC Infect Dis.* 2017;**17**:35
120. Callander D, Read P, Prestage G, Minichiello V, Chow E, **Lewis D**, McNulty A, Hammad A, Hellard M, Guy R, Donovan B. A cross-sectional study of HIV and sexually transmissible infections among male sex workers attending Australian sexual health clinics. *Sex. Transm. Infect.* 2017;**93**:299-302
121. Chow EPF, Walker S, Hocking JS, Bradshaw CS, Chen MY, Law MG, Tabrizi SN, Howden BP, Law MG, Maddaford K, Read TRH, **Lewis DA**, Whiley DM, Zhang L, Grulich AE, Kaldor JM, Cornelisse VJ, Phillips S, Donovan B, McNulty AM, Templeton DJ, Roth N, Moore R, Fairley CK. A multicentre double-blind randomised controlled trial evaluating the efficacy of daily use of antibacterial mouthwash against oropharyngeal gonorrhoea among men who have sex with men: the OMEGA (Oral Mouthwash use to Eradicate Gonorrhoea) study protocol. *BMC Infect. Dis.* 2017;**17**:456
122. Chow EPF, Callander D, Fairley CK, Zhang L, Donovan B, Guy R, **Lewis DA**, Hellard M, Read P, Ward A, Chen MY. Increased syphilis testing of men who have sex with men: greater detection of asymptomatic early syphilis and relative reduction in secondary syphilis. *Clin. Infect. Dis.* 2017;**65**:389-395
123. Hadfield J, Harris SR, Seth-Smith HMB, Parmar S, Andersson P, Giffard PM, Schachter J, Moncada J, Ellison L, Valet MLG, Fermepin MR, Radebe F, Mendoza S, Ouburg S, Morré SA, Sachse K, Puolakkainen M, Korhonen SJ, Sonnex C, Wiggins R, Jalal H, Brunelli T, Casprini P, Pitt R, Ison C, Savicheva A, Shipitsyna E, Hadad R, Kari L, Burton MJ, Mabey D, Solomon AW, **Lewis D**, Marsh P, Unemo M, Clarke IN, Parkhill J, Thomson NR. Comprehensive global genome dynamics of *Chlamydia trachomatis* show ancient diversification followed by contemporary mixing and recent lineage expansion. *Genome Res.* 2017;**27**:1220-1229
124. Alirol E, Wi TE, Bala M, Bazzo ML, Chen X, Deal C, Dillon JR, Kularatne R, Heim J, Hooft van Huijsduijnen R, Hook EW, Lahra MM, **Lewis DA**, Ndowa F, Shafer WM, Tayler

- L, Workowski K, Unemo M, Balasegaram M. Multidrug-resistant gonorrhea: A research and development roadmap to discover new medicines. *PLoS Med* 2017;14(7):e1002366
125. Tomlins L, Sawleshwarkar S, **Lewis DA**. Responding to Australia's chlamydial epidemic. *Medicine Today* 2017;18:54-57
126. Zhang L, Regan DG, Chow EPF, Gambhir M, Cornelisse V, Grulich A, Ong J, **Lewis DA**, Hocking J, Fairley CK. *Neisseria gonorrhoeae* transmission among men who have sex with men: an anatomical site-specific mathematical model evaluating the potential preventive impact of mouthwash. *Sex. Transm. Dis.* 2017;44:586-592
127. Lennard K, Dabee S, Barnabas SL, Havyarimana E, Blakney A, Jaumdally SZ, Botha G, Mkhize NN, Bekker L, **Lewis DA**, Gray G, Mulder N, Passmore JS, Jaspan H. Microbial composition predicts genital tract inflammation and persistent bacterial vaginosis in South African adolescent females. *Infection and Immunity* 2018;86:e00410-00417
128. Rietmeijer CA, Mungati M, Machiha A, Mugurungi O, Kupara V, Rodgers L, Kilmarx PH, Herman-Roloff A, Gonese E, Tippet-Barr BA, Shambira G, **Lewis DA**, Handsfield HH, Tshimanga M. The etiology of male urethral discharge in Zimbabwe: results of the Zimbabwe STI Etiology Study. *Sex. Transm. Dis.* 2018;45:56-60
129. Mungati M, Machiha A, Mugurungi O, Tshimanga M, Kilmarx PH, Nyakura J, Shambira G, Kupara V, **Lewis DA**, Gonese E, Tippet-Barr BA, Handsfield HH, Rietmeijer CA. The etiology of genital ulcer disease and coinfections with *Chlamydia trachomatis* and *Neisseria gonorrhoeae* in Zimbabwe: Results from the Zimbabwe STI Etiology Study. *Sex. Transm. Dis.* 2018;45:61-68
130. Mbulawa ZZA, Van Schalkwyk C, Hu N, Meiring TL, Barnabas S, Dabee S, Jaspan H, Kriek J, Jaumdally SZ, Muller E, Bekker L, **Lewis DA**, Dietrich J, Gray G, Passmore JS, Williamson A. High human papillomavirus (HPV) prevalence in South African adolescents and young women encourages expanded HPV vaccination campaigns. *PLoS One* 2018;13:e0190166
131. Callander D, McManus H, Guy R, Hellard M, O'Connor CC, Fairley CK, Chow EPF, McNulty A, **Lewis DA**, Carmody C, Schmidt HMA, Kim J, Donovan B. Rising chlamydia and gonorrhoea incidence and associated risk factors among female sex workers in Australia: a retrospective cohort study. *Sex. Transm. Dis.* 2018;45:199-206
132. Jamil MS, McManus H, Callander D, Prestage G, Ali H, O'Connor CC, Chen M, McNulty AM, Knight V, Duck T, Keen P, Gray J, Medland N, Hellard M, **Lewis DA**, Grulich AE, Kaldor JM, Fairley CK, Donovan B, Guy RJ. Understanding the targeting and uptake of HIV testing among gay and bisexual men attending sexual health clinics. *AIDS Behav.* 2018;22:513-521
133. Kularatne RS, Müller EE, Maseko DV, Kufa-Chakezha T, **Lewis DA**. Trends in the prevalence of genital ulcer disease pathogens and association with HIV infection in Johannesburg, South Africa 2007-2015. *PLoS One* 2018;13(4):e0194125

134. Barnabas SL, Dabee S, Passmore JS, Jaspan HB, **Lewis DA**, Jaumdally SZ, Gamieldeen H, Masson L, Muller E, Maseko VD, Mkhize N, Mbulawa Z, Williamson A, Gray CM, Hope TJ, Chiodi F, Dietrich J, Gray G, Bekker L. Converging epidemics of sexually transmitted infections and bacterial vaginosis in southern African female adolescents at risk of HIV. *Int. J. STD AIDS* 2018;**29**:531-539
135. Kilmarx PH, Gonese E, **Lewis DA**, Chirenje ZM, Tippet-Barr BA, Latif AS, Gwanzura L, Handsfield HH, Machiha A, Mugurungi O, Rietmeijer CA. HIV Infection in patients with sexually transmitted infections in Zimbabwe – results from the Zimbabwe STI etiology study. *PLoS ONE* 2018;**13**(6):e0198683
136. Cornelisse VJ, Walker S, Phillips T, Hocking JS, Bradshaw CS, **Lewis DA**, Grulich AE, Fairley CK, Chow EPF. Risk factors for oro-pharyngeal gonorrhoea in men who have sex with men: an age matched case-control study. *Sex. Transm. Infect.* 2018;**94**:359-364
137. Balle C, Lennard K, Dabee S, Barnabas SL, Jaumdally SZ, Gasper MA, Maseko V, Mbulawa ZZA, Williamson A, Bekker L, **Lewis DA**, Passmore JS, Jaspan HB. Endocervical and vaginal microbiota in South African adolescents with asymptomatic *Chlamydia trachomatis* infection. *Sci Rep* 2018;**8**:11109
138. Couldwell DL, Jalocon D, Power M, Jeoffreys NJ, Chen SC, **Lewis DA**. *Mycoplasma genitalium*: high prevalence of resistance to macrolides and frequent anorectal infection in men who have sex with men in western Sydney. *Sex. Transm. Infect.* 2018;**94**:406-410
139. Grulich AE, Guy R, Amin J, Jin F, Selvey C, Holden J, Schmidt HA, Zablotska I, Price K, Whittaker B, Chant K, Cooper C, McGill S, Telfer B, Yeung B, Levitt G, Ogilvie EE, Dharan NJ, Hammoud MA, Vaccher S, Watchirs-Smith L, McNulty A, Smith DJ, Allen DM, Baker D, Bloch M, Bopage RI, Brown K, Carr A, Carmody CJ, Collins KL, Finlayson R, Foster R, Jackson EY, **Lewis DA**, Lusk J, O'Connor CC, Ryder N, Vlahakis E, Read P, Cooper DA. Population-level effectiveness of rapid, targeted, high-coverage roll-out of HIV pre-exposure prophylaxis in men who have sex with men: the EPIC-NSW prospective cohort study. *Lancet HIV* 2018;**5**(11):e629-e637
140. Kaida A, Dietrich JJ, Laher F, Beksinka M, Jaggernath M, Bardsley M, Smith P, Cotton L, Chitneni P, Closson K, **Lewis DA**, Smit J, Ndung'u T, Brockman M, Gray G. A high burden of asymptomatic genital tract infections undermines the syndromic management approach among adolescents and young adults in South Africa: implications for HIV prevention efforts. *BMC Infect. Dis.* 2018;**18**:499
141. Rametse CL, Adefuye AO, Olivier AJ, Curry L, Gamieldeen H, Burgers WA, **Lewis DA**, Williamson A, Katz AA, Passmore JS. Inflammatory cytokine profiles of semen influence cytokine responses of cervicovaginal epithelial cells. *Front. Immunol.* 2018;**9**:2721
142. Venter JME, Mahlangu P, Müller E, **Lewis DA**, Rebe K, Struthers H, McIntyre J, Kularatne R. Comparison of an in-house real-time duplex PCR assay with commercial HOLOGIC® APTIMA assays for the detection of *Neisseria gonorrhoeae* and *Chlamydia trachomatis* in urine and extra-genital specimens. *BMC Infect. Dis.* 2019;**19**(1):6

143. Müller EE, Mahlangu MP, **Lewis DA**, Kularatne RS. Macrolide and fluoroquinolone resistance-associated mutations in *Mycoplasma genitalium* in Johannesburg, South Africa 2007-2014. BMC Infect. Dis. 2019;**19**:148
144. McManus H, Callandar D, Donovan B, Russell D, O'Connor CC, Davies SC, **Lewis DA**, Hellard ME, Chen M, Petoumenos K, Varma R, Cogle A, Boyd MA, Vlahakis E, Grulich AE, Pollard J, Medland NA, Fairley CK, Guy RJ. Early initiation of antiretroviral therapy for people newly diagnosed with HIV infection in Australia: trends and predictors, 2004-2015. Med J Aust 2019;**210**:269-275
145. Dabee S, Barnabas SL, Lennard KS, Jaumdally SZ, Gamielien H, Balle C, Happel AU, Murugan BD, Williamson A, Mkhize N, Dietrich J, **Lewis DA**, Chiodi F, Hope TJ, Shattock R, Gray G, Bekker L, Jaspan HB, Passmore JS. Defining characteristics of genital health in South African adolescent girls and young women at high risk for HIV infection. PLoS ONE 2019;**14**:e0213975
146. Rietmeijer CA, Mungati M, Kilmarx PH, Tippet Barr B, Gonese E, Kularatne RS, **Lewis DA**, Klausner JD, Rodgers L, Handsfield HH. Serological Markers for Syphilis Among Persons Presenting with Syndromes Associated with Sexually Transmitted Infections Results from the Zimbabwe STI Etiology Study. Sex. Transm. Dis. 2019;**46**:579-583
147. Lennard K, Dabee S, Barnabas S, Havyarimana E, Blakney A, Jaumdally SZ, Botha G, Mkhize NN, Bekker L, **Lewis DA**, Gray G, Mulder N, Passmore J, Jaspan H. Vaginal microbiota varies by geographical location in South African women. South African Journal for Science and Technology 2019;**38**(1)
148. Rietmeijer CA, Mungati M, Kilmarx PH, Tippet Barr B, Gonese E, Kularatne RS, **Lewis DA**, Klausner JD, Rodgers L, Handsfield HH. Performance of a dual human immunodeficiency virus/syphilis rapid test compared to conventional serological testing for syphilis and HIV in a laboratory setting - results of the Zimbabwe STI Etiology Study. Sex. Transm. Dis 2019;**46**:584-587
149. **Lewis DA**. New treatment options for *Neisseria gonorrhoeae* in the era of emerging antimicrobial resistance. Sex. Health 2019;**16**:449-456
150. **Lewis DA**. Disentangling the tangled web of *Neisseria gonorrhoeae* transmission: how important are oro-pharyngeal infections? Sex. Transm. Infect. 2019;**95**:395-396
151. Gray CM, O'Hagan KL, Lorenzo-Redondo R, Olivier AJ, Amu S, Chigorimbo-Tsikiwa N, Harryparsad R, Sebaa S, Maziya L, Dietrich J, Ot wombe K, Martinson N, Ferrian S, Mkhize NN, **Lewis DA**, Lang D, Carias AM, Jaspan HB, Wilson DPK, McGilvray M, Cianci GC, Anderson MR, Dinh MH, Williamson AL, Passmore JS, Chiodi F, Hope TJ. Impact of chemokine C-C ligand 27, foreskin anatomy and sexually transmitted infections on HIV-1 target cell availability in adolescent South African males. Mucosal Immunology 2020;**13**:118-127

152. Murray D, Mao L, Wong T-H, Chen T, Mackie B, Kao S-C, Haque AH, Dabbhadatta J, Prihaswan P, Stackpool G, Brooks M, Brown G, **Lewis D**. High levels of engagement with testing for HIV and sexually transmissible infection among gay Asian men in Sydney and Melbourne: an observational study. *Sexual Health* 2020;**17**:121-128.
153. Ooi C, Kong FYS, **Lewis DA**, Hocking JS. Prevalence of sexually transmissible infections and HIV in men attending sex-on-premises venues in Australia: a systematic review and meta-analysis of observational studies. *Sexual Health* 2020;**17**:135-148
154. Chitneni P, Beksinska M, Dietrich JJ, Jaggernath M, Closson K, Smith P, **Lewis D**, Matthews LT, Smit J, Ndung'u T, Brockman M, Gray G, Kaida A. Partner notification and treatment practices among South African adolescents and young adults diagnosed with a sexually transmitted infection via laboratory-based screening. *Int. J. STD AIDS* 2020;**31**:627-636
155. Lau A, King FYS, Fairley CK, Templeton DJ, Amin J, Boyd MA, Bradshaw C, Chen MY, Donovan B, Khaw C, **Lewis DA**, McNulty A, Regan DG, Ratnayake M, Hocking JS. Factors associated with early resumption of condomless anal sex among men who have sex with men after rectal chlamydia treatment. *Sex. Transm. Dis.* 2020;**47**:389-394
156. Richardson D, Chan H, Bopage R, **Lewis DA**, Sawleshwarkar S, Chung C, Kok J. HIV-1 subtype variability and transmitted drug resistance in a culturally diverse population in Western Sydney, New South Wales, Australia. *Sexual Health* 2020;**17**:377-380
157. Dabee S, Mkhize NN, Jaspan HB, **Lewis DA**, Gumbi PP, Jo-Ann S. Passmore JS. Initiation of antiretroviral therapy differentially influences genital and systemic immune activation in HIV-infected women. *AIDS Res. Hum. Retrovir.* 2020;**36**:821-830
158. Richardson D, **Lewis DA**, Jeoffreys NJ, Couldwell DL. *Mycoplasma genitalium* co-infection in men with symptomatic gonococcal urethritis. *Sex. Transm. Infect.* 2021;**97**:363-367
159. Ogunbodede OT, Zablotska-Manos I, **Lewis DA**. Potential and demonstrated impacts of the COVID-19 pandemic on sexually transmissible infections. *Curr. Opin. Infect. Dis.* 2021;**34**:56-61 (+ re-published in *Curr. Opin. HIV AIDS* 2021;**16**:115-120)
160. Hughes Y, **Lewis DA**. HSV associated proctitis presenting without perianal lesions: why testing and empirical treatment may be important. *BMJ Case Rep* 2021;**14**:e237247
161. Chow EPF, Williamson DA, Hocking JS, Law MG, Maddaford K, Bradshaw CS, McNulty A, Templeton DJ, Moore R, Murray GL, Danielewski JA, Wigan R, Chen MY, Guy RJ, Zhang L, Donovan B, Grulich AE, Kaldor JM, Whiley DM, Cornelisse VJ, Howden BP, **Lewis DA**, Read TRH, Fairley CK. Antiseptic mouthwash for gonorrhoea prevention (OMEGA): a randomised, double-blind, parallel-group, multicentre trial. *Lancet Infect. Dis.* 2021;**21**:647-656

162. Armstrong BH, Limnios A, Lewis DA, Hogan T, Kundu R, Ray S, Shoushtari M, El Nasser J, Driscoll T, Lahra MM. Is gentamicin a viable therapeutic option for treating resistant *Neisseria gonorrhoeae* in NSW? *Commun Dis Intell* (2018) 2021;Feb 26;45.
163. Bavinton BR, Vaccher S, Jin F, Prestage GP, Holt M, Zablotska-Manos IB, Guy R, Amin J, Templeton DJ, Yeung B, Hammoud MA, **Lewis D**, Baker D, Dharan N, McNulty AM, Grulich AE. High levels of prevention-effective adherence to HIV pre-exposure prophylaxis (PrEP): An analysis of sub-study data from the EPIC-NSW trial. *J. Acquir. Immune Defic. Syndr.* 2021;**87**(4):1040-1047
164. Ubrihien AJ, Gwynne K, **Lewis DA**. Enabling culturally safe sexual health services in western Sydney: a protocol to improve STI treatment outcomes for Aboriginal young people. *Pilot Feasibility Stud.* 2021;**7**:106
165. Seth-Smith HMB, Bénard A, Bruisten SM, Versteeg B, Herrmann B, Kok J, Carter I, Peuchant O, Bébéar C, **Lewis DA**, Puerta T, Kese D, Balla E, Zákoucká H, Rob F, Morré SA, de Barbeyrac B, Galán JC, de Vries HJC, Thomson NR, Goldenberger D, Egli A. Ongoing evolution of *Chlamydia trachomatis* lymphogranuloma venereum: exploring the genomic diversity of circulating strains. *Microbial Genomics* 2021;**7**:000599
166. Lau A, Kong FYS, Fairley CK, Templeton DJ, Amin J, Phillips S, Law M, Chen MY, Bradshaw CS, Donovan B, McNulty A, Boyd MA, Timms P, Chow EPF, Regan DG, Khaw C, **Lewis DA**, Kaldor J, Ratnayake M, Carvalho N, Hocking JS. Azithromycin or doxycycline for asymptomatic rectal *Chlamydia trachomatis*. *N. Engl. J. Med.* 2021;**384**:2418-2427
167. Grulich AE, Jin F, Bavinton BR, Yeung B, Hammoud MA, Amin J, Cabrera G, Clackett S, Ogilvie E, Vaccher S, Vickers T, McNulty A, Smith DJ, Dharan NJ, Selvey C, Power C, Price K, Zablotska I, Baker DA, Bloch M, Brown K, Carmody C, Carr A, Chaniseff D, Doong N, Finlayson R, **Lewis DA**, Lusk J, Martin S, Ooi C, Read P, Ryder N, Smith D, Soo CTM, Templeton DJ, Vlahakis E, Guy R. Long-term protection from HIV infection with oral HIV pre-exposure prophylaxis in gay and bisexual men: findings from the expanded and extended EPIC-NSW prospective implementation study. *Lancet HIV* 2021;**8**:e486-494
168. Ooi C, Donovan B, **Lewis DA**. Cross-sectional study of sexual behaviour and health of gay and bisexual men in suburban Sydney, New South Wales, Australia: contrasts between sex venue and clinic attendees. *Sex. Health* 2021;**18**(3):248-253
169. Power M, Dong K, Walsh J, **Lewis D**, Richardson D. Barriers to HIV testing in hospital settings within a culturally diverse urban district of Sydney, Australia. *Sex. Health* 2021;**18**:340-343
170. Kularatne RS, Kufa T, Gumede L, Maseko DV, **Lewis DA**. Demographic and behavioral risk factors associated with reduced susceptibility of *Neisseria gonorrhoeae* to first-line antimicrobials in South African men with gonococcal urethral discharge. *Antimicrob. Agents Chemother.* 2021;**65**:e00389-21

171. Duan Q, Carmody C, Donovan B, Guy RJ, Hui BB, Kaldor JM, Lahra M, Law MG, **Lewis DA**, Maley M, McGregor S, McNulty A, Selvey C, Templeton DJ, Whiley DM, Regan DG, Wood JG. Modelling response strategies for controlling gonorrhoea outbreaks in men who have sex with men in Australia. *PLoS Comput. Biol.* 2021;**17**(11):e1009385
172. Herbert SE, Pühr R, Petoumenos K, **Lewis DA**, Varma R, Couldwell DL, Law M, Templeton D. Characteristics of heterosexually-acquired compared to homosexually-acquired HIV and implications for clinical practice: results from the Australian HIV observational database. *AIDS Care* 2022;**34**:626-632.
173. Hui BB, Padeniya TN, Rebuli N, Gray RT, Wood JG, Donovan B, Duan Q, Guy R, Hocking JS, Lahra MM, **Lewis DA**, Whiley DM, Regan DG, Seib KL. A gonococcal vaccine has the potential to rapidly reduce the incidence of *Neisseria gonorrhoeae* infection among urban men who have sex with men. *J. Infect. Dis.* 2022;**225**(6):983-993
174. Medland NA, Zhang Y, Gunaratnam P, **Lewis DA**, Donovan B, Whiley DM, Guy RJ, Kaldor JM. Surveillance systems to monitor antimicrobial resistance in *Neisseria gonorrhoeae*: a global, systematic review. 1 January 2012 to 27 September 2020. *Eurosurveill.* 2022;**27**(18):2100917
175. Ubrihien A, Gwynne K, **Lewis DA**. Barriers and enablers for young Aboriginal people in accessing public sexual health services: A mixed method systematic review. *Int. J. STD AIDS* 2022;**33**(6):559-569
176. Mason E, Tomlins L, **Lewis DA**. Sexually transmissible infections: current approaches to management. *S. Afr. Gen. Pract.* 2022;**3**(3):89-94
177. Ooi C, **Lewis DA**, Newman C. Engaging hard-to-reach men-who-have-sex-with-men with sexual health screening: qualitative interviews in an Australian sex-on-premises-venue and sexual health service. *Perspect. Sex. Reprod. Health* 2022;**54**(3):116-124
178. Jennings JM, Grieb SM, Rietmeijer C, Gaydos CA, Hawkins R, Thurston RC, Blanchard J, Cameron CE, **Lewis DA**. Advancing sexual harassment prevention and elimination in the Sciences: “Every sexual health organization must do something similar.” *Sex. Transm. Infect.* 2022;**49**(10):663-668
179. Chigorimbo-Murefu NTL, Potgieter M, Dzanibe S, Gabazana Z, Buri G, Chawla A, Nleya B, Olivier AJ, Harryparsad R, Calder B, Garnett S, Maziya L, **Lewis DA**, Jaspan H, Wilson D, Passmore JS, Mulder N, Blackburn J, Bekker L, Gray CM. A pilot study to show that asymptomatic sexually transmitted infections alter the foreskin epithelial proteome. *Front. Microbiol.* 2022;**13**:928317
180. Kong FYS, Unemo M, Lim SH, Latch N, Williamson DA, Roberts JA, Wallis SC, Parker SL, Landersdorfer CB, Yap T, Fairley CK, Chow EPF, **Lewis DA**, Hammoud MA, Hocking JS. Optimisation of treatments for oral *Neisseria gonorrhoeae* infection: Pharmacokinetics Study (STI-PK project) - study protocol for non-randomised clinical trial. *BMJ Open* 2022;**12**(11):e064782

181. Heron JE, McManus H, Vickers T, Ryan K, Wright E, Carter A, Stooove M, Asselin J, Grulich A, Donovan B, Guy R, Varma R, Chen M, Ryder N, **Lewis DA**, Templeton DJ, O'Connor CC, Gracey DM. Renal impairment associated with tenofovir disoproxil fumarate for antiretroviral therapy and HIV pre-exposure prophylaxis: an observational cohort study. *PLoS One* 2023;**18**(2):e0280339
182. Ubrihien A, **Lewis DA**, Rambaldini B, Kirwan Morwenna, Gwynne K. Clinicians' perspectives on why young Aboriginal people are not testing for sexually transmissible infections in western Sydney. *Int. J. STD AIDS* 2023;**34**(1):803-808
183. Bell SFE, Ware RS, **Lewis DA**, Lahra MM, Whiley DM. Antimicrobial susceptibility assays for *Neisseria gonorrhoeae*: a proof-of-principle population-based retrospective analysis. *Lancet Microbe* 2023;**4**(7):e544-e551
184. Perry CR, Scangarella-Oman NE, Millns H, Flight W, Gatsi S, Jakielaszek C, Janmohamed S, **Lewis DA**. Efficacy and safety of Gepotidacin as treatment of uncomplicated urogenital gonorrhoea (EAGLE-1): Design of a randomised, comparator-controlled, Phase 3 study. *Clin. Drug. Investig.* 2023;**12**(9):2307-2320
185. Seib KL, Donovan B, Thng C, **Lewis DA**, McNulty A, Fairley CK, Yeung B, Jin J, Fraser D, Bavington BR, Law M, Chen MY, Whiley DM, Mackie B, Heslop A, Grulich AE. A multicentre double-blind randomised placebo-controlled trial evaluating the efficacy of the meningococcal B vaccine, 4CMenB (Bexsero), against *Neisseria gonorrhoeae* infection in men who have sex with men: the GoGoVax study Protocol. *BMJ Open* 2024;**14**(4):e081675
186. Mason E, **Lewis DA**, Zablotska I, Tomlins L. Using a patient reported outcome measure to assess quality of life at Western Sydney Sexual Health Centre. *Sexual Health* 2024 Jul;**21**:SH24040. doi: 10.1071/SH24040
187. Perera M, Gilroy N, **Lewis DA**, Ferguson PE. Evaluation of preventive medicine amongst people living with HIV attending a hospital-based care setting. *Intern Med J.* 2025;**55**(4):581-588
188. Ross JDC, Wilson J, Workowski KA, Taylor SN, **Lewis DA**, Gatsi S, Flight W, Scangarella-Oman NE, Jakielaszek C, Lythgoe D, Powell M, Janmohamed S, Absalon J, Caroline Perry. Phase 3 randomised trial of oral gepotidacin for the treatment of uncomplicated gonorrhoea (EAGLE-1). *Lancet* 2025;**405**:1608-1620
189. Drak D, McManus H, Vickers T, Salerno J, Tobin M, Hughes J, **Lewis DA**, Carter C, Russell D, Gunathilake M, Guy R, O'Connor CC, Ward J, Gracey DM. Pre-exposure prophylaxis (PrEP) and renal impairment risk in Aboriginal and Torres Strait Islander Australians. *Sexual Health* 2025;**22**:SH24149 doi:10.1071/SH24149
190. **Lewis DA**. Gonorrhoea. *Clin. Dermatol.* Published ahead of print 2025 Sep 29:S0738-081X(25)00221-4.



191. **Lewis DA.** Chancroid. In: Clin. Dermatol. Published ahead of print Oct 3:S0738-081X(25)00250-0

## BOOK CONTRIBUTIONS

1. **Lewis DA.** Trichomoniasis. *MEDICINE* 2010;**38(6)**:291-293
2. Ison CA and **Lewis DA.** Gonorrhea. In: *Atlas of Sexually Transmitted Diseases and AIDS, 4<sup>th</sup> Edition* (2010)
3. **Lewis DA.** Sexual healthcare in resource poor settings. In: *ABC of Sexually Transmitted Infections, 6<sup>th</sup> Edition* (2011)
4. **Lewis D.** Chancroid. In: *Laboratory diagnosis of sexually transmitted infections, including human immunodeficiency virus* (2013)
5. **Lewis D.** Donovanosis (granuloma inguinale). In: *Laboratory diagnosis of sexually transmitted infections, including human immunodeficiency virus* (2013)
6. Revision of Section 3.9.4 on *Haemophilus ducreyi* cultures. In: *Aerobic Bacteriology in the Clinical Microbiology Procedures Handbook* (2014)
7. **Lewis DA,** von Knorring N. Sexually transmitted infections: diagnosis and treatment. In: *MIMS Handbook of Infectious Diseases* volume 1 (2014)
8. **Lewis DA.** Gonorrhea. Chapter 53 in: Hunter's Tropical Medicine and Emerging Infectious Disease, 10<sup>th</sup> Edition (2018)
9. **Lewis D,** Unemo M. Chancroid. In: *Laboratory diagnosis of sexually transmitted infections, including human immunodeficiency virus* (2023)
10. **Lewis D,** Unemo M. Donovanosis (granuloma inguinale). In: *Laboratory diagnosis of sexually transmitted infections, including human immunodeficiency virus* (2023)
11. **Lewis D,** Wald A. Herpes simplex virus (HSV) infections. In: *Laboratory diagnosis of sexually transmitted infections, including human immunodeficiency virus* (2023)

## LETTERS

1. Zumla A, **Lewis DA,** Brown J. Ciprofloxacin treatment of recurrent Salmonella septicaemia in a splenectomised and immunosuppressed patient. J. Antimicrob. Chemother. 1988;**21**:809-810.
2. Brook G, Karet F, **Lewis DA,** Uriel AJ, Weir WRC. Interpretation of blood films in diagnosis of malaria. Lancet 1989;**ii**:619
3. **Lewis DA,** Jenks P, Gent AEM, Side L, Breuer J. Varicella-zoster vaccination for health care workers. Lancet 1994;**343**:1362-1363

4. **Lewis DA**, Forster GE, Goh BT. Ciprofloxacin resistant gonococci arriving from Thailand. *Genitourinary Med.* 1994;**70**:360
5. **Lewis DA**, Forster GE, Goh BT. The falling accuracy of microscopy in the diagnosis of gonorrhoea - a cause for concern? *Genitourin. Med.* 1995;**71**:136
6. **Lewis DA**, Goldmeier D. The cost effectiveness of hospital-based 25% podophyllin vs. home-based 0.5% podophyllotoxin in the treatment of anogenital warts. *Int. J. STD & AIDS* 1995;**6**:224
7. **Lewis DA**, Forster GE, Goh BT. Gonorrhoea in HIV seropositive homosexual men attending an East London genitourinary medicine clinic. *Genitourin. Med.* 1996;**72**:74
8. Wilson P, **Lewis D**, Jenks P, Hoque S. Prevalence of antibiotic resistance in pneumococci - prevalence of resistance to penicillin is higher in east London. *Br. Med. J.* 1996;**313**:819-820
9. **Lewis DA**, Shafi MS, Brook G. High level ciprofloxacin resistant gonorrhoea imported from Russia. *Genitourin. Med.* 1997;**73**:325-326
10. **Lewis DA**. Update on the experimental human model for chancroid infection. *Int. J. STD and AIDS* 2000;**11**:68-69
11. Tong CYW, Dunn H, **Lewis DA**. Opportunistic screening for Chlamydia: microbiological input is essential in chlamydia screening programmes. *Br. Med. J.* 2003;**327**:290
12. Gray C, Hong H, Young K, **Lewis DA**, Fallows D, Manca C, Kaplan G. Plasma interferon-gamma-inducible protein-10 (IP-10) can be used to predict viral load in HIV-1 infected individuals. *J. Acquir. Immune Defic. Syndr.* 2013;**63**:e115-e116
13. Seth-Smith HM, Galán JC, Goldenberger D, **Lewis DA**, Peuchant O, Bébéar C, de Barbeyrac B, Bénard A, Carter I, Kok J, Bruisten SM, Versteeg B, Morré SA, Thomson NR, Egli A, de Vries HJ. Concern regarding the alleged spread of hypervirulent lymphogranuloma venereum Chlamydia trachomatis strain in Europe. *Euro. Surv.* 2017;**22**(15):pii30511
14. Gunaratnam P, McManus H, Watchirs-Smith L, McGregor S, Callander D, Brown G, Lobo R, O'Connor CC, Hellard M, Medland N, **Lewis D**, Palmer C, Law M, Gray R, Donovan B, Guy R. People born in non-English speaking countries are less likely to start HIV treatment early in Australia: A national cohort analysis, 2014-15. *J. Acquir. Immun. Def. Syndr.* 2018;**77**:e31-e34
15. Power M, **Lewis DA**, Richardson D. On-demand HIV pre-exposure prophylaxis: what are the healthcare workers' barriers to delivery in a culturally and linguistically diverse population? *Sex. Transm. Infect.* 2020;**96**:549

16. Hutchinson J, **Lewis D**, Law M, Bavinton B, Puh R, Petoumenos K. Clinical characteristics of overseas born men who have sex with men (MSM) in the AHOD cohort and implications for clinical practice. *Sex. Transm. Infect.* 2020;**96**:469-470
17. Richardson D, Jaricha T, Power M, **Lewis D**. Team-huddles in sexual health clinics improve communication, clinic capacity & flow and team relationships. *Sex. Transm. Infect.* 2020;**96**:312
18. Richardson D, Kumar P, Jaricha T, Walsh J, **Lewis DA**. Primary syphilis in men causes painful anogenital lesions and serology isn't always helpful. *Sex. Transm. Infect.* 2020;**96**:620
19. Richardson D, Shapiro J, **Lewis DA**, Zablotska I. Inconsistent HIV pre-exposure prophylaxis use and HIV transmission in men who have sex with men (MSM). *J. Int. AIDS Soc.* 2020;**23**:e25579
20. Richardson D, Pinto-Sander N, Kumar P, Jaricha T, Walsh J, **Lewis D**. How would sexual health clinicians manage first attendance of men who have sex with men with ano-genital ulcers? *Int. J. STD AIDS* 2021;**32**:382-383
21. Shapiro J, Hoskins F, Bopage R, Chung C, Power M, **Lewis DA**, Richardson D. A pilot study: the influence of staff attitudes and beliefs on managing contacts of sexually transmitted infections. *J. Pub Health* 2021;**43**(1):e120.

## INVITED PRESENTATIONS

1. **Lewis DA**. Modern methods for the diagnosis of genital ulcer disease. **Symposium presentation** at the 10th Congress of the European Academy of Dermatology and Venereology, Munich, Germany, 10-13 October 2001
2. **Lewis DA**. Chancroid: clinical aspects, diagnosis and treatment in the 21<sup>st</sup> century. **Symposium presentation** at the 7th International Conference of *H. ducreyi* Pathogenesis and Chancroid, Ottawa, Canada, 27 July 2003
3. **Lewis DA**. STIs in the HIV era. **Symposium presentation** at the International Medical Sciences Academy Annual Conference, Kerala, India, 26 September 2003
4. **Lewis DA**. Chancroid: from clinical practice to basic science. **Symposium presentation** at the International Union against Sexually Transmitted Infections Asia Pacific meeting, Chiang Mai, Thailand, 6-9 July 2004
5. **Lewis DA**. The role of the laboratory in the diagnosis of STI in women. **Symposium presentation** at the Sexually Transmitted Infections, HIV, Gender and Violence conference, Lisbon, Portugal, 8-9 May 2005

6. **Lewis DA.** Treatment of chancroid in 2005. **Symposium presentation** at the 8<sup>th</sup> International Symposium on *Haemophilus ducreyi* pathogenesis and chancroid, Amsterdam, The Netherlands, 10 July 2005
7. **Lewis DA.** Quinolone resistant gonococci: cause for concern? **Key note address** at Simunye 2005, 1<sup>st</sup> joint Congress of the Federation of Infectious Diseases Societies in South Africa, Sun City, South Africa, 24-27 July 2005
8. **Lewis DA.** Lessons from South Africa. **Invited lecture** at the British Association of Sexual Health and HIV Spring Meeting, Nottingham, UK, 17-19 May 2006
9. **Lewis DA.** The changing tide of STIs in South Africa. **Symposium presentation** at the 14<sup>th</sup> IUSTI-Asia Pacific Congress, Kuala Lumpur, Malaysia, 27-30 July 2006
10. **Lewis DA.** Acute HIV infection and genital ulceration: double trouble. **Symposium presentation** at the 14<sup>th</sup> IUSTI-Asia Pacific Congress, Kuala Lumpur, Malaysia, 27-30 July 2006
11. **Lewis DA.** Controlling the HIV Epidemic in South Africa: Future Challenges. **Symposium presentation** at the 22<sup>nd</sup> IUSTI-Europe Conference, Versailles, France, 19-21 October 2006
12. **Lewis DA.** The declining prevalence of *H. ducreyi* in previously endemic area: hypotheses and implications for syndromic management and clinical and basic research. **Symposium presentation** at the 7<sup>th</sup> International Symposium on *Haemophilus ducreyi* pathogenesis and chancroid, 17<sup>th</sup> Meeting of the International Society for STD Research and 10<sup>th</sup> World Congress of the International Society against STIs, Seattle, USA, July 29-August 1, 2007
13. **Lewis DA.** Challenges for Africa: antibiotic resistance, changing STI aetiologies and devastation by HIV. **Symposium presentation** at the 17<sup>th</sup> Meeting of the International Society for STD Research and 10<sup>th</sup> World Congress of the International Society against STIs, Seattle, USA, 29 July-1 August 2007
14. **Lewis DA.** HIV and women: the African Experience. **Invited talk** at the Australasian Sexual Health Conference 2007, Gold Coast, Australia, 8-10 October 2007
15. **Lewis DA.** Measuring trends in STI syndrome aetiologies and antibiotic resistance patterns: the South African experience. **Invited talk** at the Australasian Sexual Health Conference 2007, Gold Coast, Australia, 8-10 October 2007
16. **Lewis DA.** Treating antibiotic resistant gonorrhoea. **Symposium presentation** at the BASHH-ASTDA 3<sup>rd</sup> joint conference, New York, USA, 7-10 May 2008
17. **Lewis DA.** Better management of STIs: strategic approaches and current threats to HIV prevention. **Symposium presentation** at the 2<sup>nd</sup> Botswana International HIV Conference, Gaborone, Botswana, 17-20 September 2008

18. **Lewis DA.** Chancroid: a historical perspective. **Symposium presentation** at the 10<sup>th</sup> International Symposium on *Haemophilus ducreyi* pathogenesis and chancroid, London, UK, 28 June 2009
19. **Lewis DA.** The gonococcus fights back – this time is it a knock out? **Plenary presentation** at the 18<sup>th</sup> Meeting of the International Society for STD Research, London, UK, 28 June – 1 July 2009
20. **Lewis DA.** From mice to men: an overview of trichomoniasis. **Symposium presentation** at the 3<sup>rd</sup> Meeting of the Federation of Infectious Diseases Societies of Southern Africa, Sun City, South Africa, 20-23 August 2009
21. **Lewis DA.** Non-STI causes of genital ulceration: Behçet's disease. **Symposium presentation** at the 3<sup>rd</sup> Meeting of the Federation of Infectious Diseases Societies of Southern Africa, Sun City, South Africa, 20-23 August 2009
22. **Lewis DA.** STI/HIV: regional challenges for Africa. **Symposium presentation** at the 11<sup>th</sup> International Union against STIs World Congress, Cape Town, South Africa, 9-12 November 2009
23. **Lewis DA.** Antimicrobial resistance in gonorrhoea. **Symposium presentation** at the 8<sup>th</sup> Congress of the Brazilian STD Society, the 4<sup>th</sup> Brazilian Congress of AIDS and the 1<sup>st</sup> ALAC-STD Congress, Curitiba, Brazil, 18-21 May 2011
24. **Lewis DA.** Management of metronidazole treatment failures. **Symposium presentation** at the 8<sup>th</sup> Congress of the Brazilian STD Society, the 4<sup>th</sup> Brazilian Congress of AIDS and the 1<sup>st</sup> ALAC-STD Congress, Curitiba, Brazil, 18-21 May 2011
25. **Lewis DA.** STIs and MSM: a top, front and bottom approach. **Plenary presentation** at the TOP2BTM MSM Symposium, Cape Town, South Africa, 23-25 May 2011
26. **Lewis DA.** Possible treatment strategies in an era of multi-drug resistant gonorrhoea. **Invited talk** at the Meeting of the International Collaboration on Gonococci, Québec City, Canada, 10 July 2011
27. **Lewis DA.** Failure to detect acute HIV infection: a missed opportunity for HIV prevention? **Plenary presentation** at the 4<sup>th</sup> Federation of Infectious Diseases Societies of Southern Africa Congress, Durban, South Africa, 8-11 September 2011
28. **Lewis DA.** New threats to treatment. **Plenary presentation** at the 12<sup>th</sup> International Union against STIs World Congress, New Delhi, India, 2-5 November 2011
29. **Lewis DA.** The Gonococcus: Significant Pathogen and Master of Evolutionary Adaptation. **Princess Alexandra Sexual Health (PASH) invitation lecture**, Brisbane, Australia, 8 November 2011

30. **Lewis DA.** Treatment of resistant STIs relevant to MSM. **Symposium presentation** at the TOP2BTM Changing Manscapes Symposium, Cape Town, South Africa, 20-12 August 2012
31. **Lewis DA.** Debate on rapid tests for syphilis. **Oral debate** at the PathPoint 2012 Conference, Cape Town, South Africa, 28-30 September 2012
32. **Lewis DA.** Multi-drug resistant gonorrhoea – can we hold back the tide? **Plenary presentation** at the 13<sup>th</sup> International Union against STIs World Congress, Melbourne, Australia, 15-17 October 2012
33. **Lewis DA.** Resistance patterns to third generation cephalosporins in Africa. **Symposium presentation** at the 13<sup>th</sup> International Union against STIs World Congress, Melbourne, Australia, 15-17 October 2012
34. **Lewis DA.** An overview of human papillomavirus (HPV) infections, oncogenicity and prevention. **Symposium presentation** at the ENT, Audiology, Speech and Language Congress 2012, Sun City, South Africa, 3-6 November 2012
35. **Lewis DA.** How should the laboratory respond to the public health challenge of limiting the spread of multidrug resistant gonorrhoea. **Symposium presentation** at the 1<sup>st</sup> International Conference of the African Society of Laboratory Medicine, Cape Town, South Africa, 1-7 December 2012
36. **Lewis DA.** When do we screen for STIs and when do we intervene? **Symposium presentation** at 6th South African AIDS Conference, Durban, South Africa, 18 - 21 June 2013
37. **Lewis DA.** Syphilis among mothers in Africa with an epidemiologic review/summary of prevalence. **Symposium presentation** at 6th South African AIDS Conference, Durban, South Africa, 18 - 21 June 2013
38. **Lewis DA.** Performance and current use of rapid syphilis tests. **Symposium presentation** at 6th South African AIDS Conference, Durban, South Africa, 18 - 21 June 2013
39. **Lewis DA.** Chancroid, Donovanosis and LGV. World Health Organization pre-conference **symposium presentation** at the STI and AIDS World Congress 2013 (Joint Meeting of the 20<sup>th</sup> Meeting of the International Society for STD Research and the 14<sup>th</sup> International Union against Sexually Transmitted Infections World Congress), Vienna, Austria, 14-17 July 2013
40. **Lewis DA.** Basic science track summary and highlights. **Symposium presentation** at the STI and AIDS World Congress 2013 (Joint Meeting of the 20<sup>th</sup> Meeting of the International Society for STD Research and the 14<sup>th</sup> International Union against Sexually Transmitted Infections World Congress), Vienna, Austria, 14-17 July 2013
41. **Lewis DA.** Dilemmas for the detection and diagnosis of *Neisseria gonorrhoeae* infection. **Symposium presentation** at the 9th Congress of the Brazilian Society of Sexually Transmitted Diseases, Salvador, Brazil, 18-21 August 2013

42. **Lewis DA.** Laboratory diagnostic and molecular epidemiological tools for *Neisseria gonorrhoeae* infection. **Symposium presentation** at the 9th Congress of the Brazilian Society of Sexually Transmitted Diseases, Salvador, Brazil, 18-21 August 2013
43. **Lewis DA.** The rise of resistance among STI pathogens. **Plenary lecture** at the 5<sup>th</sup> Federation of Infectious Diseases Societies of Southern Africa Congress, Durban, South Africa, 10-12 October 2013
44. **Lewis DA.** HPV - the next steps. **Invited talk** at the 10th Annual Congress on Vaccinology, Hermanus, South Africa, 14-15 October 2013
45. **Lewis DA.** Antimicrobial resistance in gonorrhoea: historical microbiological perspective and the role of core groups. **Symposium presentation** at the University of Montreal, Montreal, Canada, 21 October 2013
46. **Lewis DA.** Antibiotic resistant *Neisseria gonorrhoeae*. **Symposium presentation** at the Gairdner Foundation's Global Health Symposium, Toronto, Canada, 23 October 2013
47. **Lewis DA.** Evolution of resistance in gonorrhoea. **Symposium presentation** in an academic day organized by the British Association of HIV and Sexual Health, Sexually Transmitted Infections journal and Public Health England, London, UK, 10 December 2013
48. **Lewis DA.** Lymphogranuloma venereum. **Symposium presentation** at the 21st Conference on Retroviruses and Opportunistic Infections, Boston, USA, 3-6 March 2014
49. **Lewis DA.** Containment of antimicrobial drug resistant gonorrhoea. **Symposium presentation** at the 16th International Congress on Infectious Diseases, Cape Town, South Africa, 2-5 April 2014
50. **Lewis DA.** How to bridge the gap: the way towards the availability of STI vaccines. **Symposium presentation** at the 16th International Congress on Infectious Diseases, Cape Town, South Africa, 2-5 April 2014
51. **Lewis DA.** Where we are, where we are headed: a dialogue. **Plenary lecture** at the 2014 STD Prevention Conference, Atlanta, USA, 9-12 June 2014
52. **Lewis DA.** Is management of pharyngeal gonorrhoea crucial to prevent the emergence and spread of antibiotic-resistant *Neisseria gonorrhoeae*? **Mini-plenary lecture** at the 2014 STD Prevention Conference, Atlanta, USA, 9-12 June 2014
53. **Lewis DA.** The many facets of *Haemophilus ducreyi* infection: a multidisciplinary look at an evolving pathogen. **Gollow Keynote Lecture** at the 2014 Australasian Sexual Health Conference, Sydney, Australia, 9-11 October 2014
54. **Lewis DA.** Antimicrobial resistant gonorrhoea. **Plenary lecture** at the 18<sup>th</sup> IUSTI Asia Pacific Conference, Bangkok, Thailand, 9-12 November 2014

55. **Lewis DA.** Syphilis rapid tests: an overview of test performance in various settings. **Symposium presentation** at the 18<sup>th</sup> IUSTI Asia Pacific Conference, Bangkok, Thailand, 9-12 November 2014
56. **Lewis DA.** Treatment strategies in the MDR *Neisseria gonorrhoeae* era. **Symposium presentation** at the 18<sup>th</sup> IUSTI Asia Pacific Conference, Bangkok, Thailand, 9-12 November 2014
57. **Lewis DA.** HIV/STIs in Africa and the Asia-Pacific region – public health successes and emerging threats. **Symposium presentation** at the Marie Bashir Institute Colloquium, Sydney, Australia, 25 March 2015
58. **Lewis DA.** Viral and other causes of genital ulceration. **Symposium presentation** at the Viruses in May meeting, Katoomba, Australia, 1 May 2015
59. **Lewis DA.** Lymphogranuloma venereum and chancroid: classical STIs with new presentations. **Symposium presentation** at the joint meeting of the 10<sup>th</sup> Congress of the Brazilian STD Society and the 6<sup>th</sup> Brazilian AIDS Congress, São Paulo, Brazil, 17-20 May 2015
60. **Lewis DA.** Laboratory Diagnostic and Molecular Epidemiological Tools for *Neisseria gonorrhoeae* and *Chlamydia trachomatis*. **Symposium presentation** at the joint meeting of the 10<sup>th</sup> Congress of the Brazilian STD Society and the 6<sup>th</sup> Brazilian AIDS Congress, São Paulo, Brazil, 17-20 May 2015
61. **Lewis DA.** Syphilis pathogenesis. **Symposium presentation** at the 17<sup>th</sup> IUSTI World Congress, Marrakesh, Morocco, 9-12 May 2016
62. **Lewis DA.** Implications of PrEP for STI control programs. **Symposium presentation** at the 17<sup>th</sup> IUSTI World Congress, Marrakesh, Morocco, 9-12 May 2016
63. **Lewis DA.** Role of diagnostics in surveillance, management, and conservation of antibiotics and future development of antibiotics. **Invited talk** at a Global Antibiotic Research and Development Partnership meeting, Geneva, Switzerland, 27-28 June 2016
64. **Lewis DA.** Oral sex and STIs. **Keynote lecture** at the International Symposium on Sexually Transmitted Infection, Buenos Aires, Argentina, 3-4 November 2016
65. **Lewis DA.** Pathogenesis of syphilis. **Symposium presentation** at the International Symposium on Sexually Transmitted Infection, Buenos Aires, Argentina, 3-4 November 2016
66. **Lewis DA.** Urethral discharge in men. **Symposium presentation** at the International Symposium on Sexually Transmitted Infection, Buenos Aires, Argentina, 3-4 November 2016



67. **Lewis DA.** Antimicrobial resistance of *Neisseria gonorrhoeae*. **Symposium presentation** at the International Symposium on Sexually Transmitted Infection, Buenos Aires, Argentina, 3-4 November 2016
68. **Lewis DA.** Trichomoniasis – a forgotten problem? **Plenary lecture** at the 19<sup>th</sup> IUSTI Asia Pacific Conference, Okayama City, Japan, 1-3 December 2016
69. **Lewis DA.** Molecular characteristics of syphilis. **Symposium presentation** at the 19<sup>th</sup> IUSTI Asia Pacific Conference, Okayama City, Japan, 1-3 December 2016
70. **Lewis DA.** What reviewers expect. **Symposium presentation** at the 19<sup>th</sup> IUSTI Asia Pacific Conference, Okayama City, Japan, 1-3 December 2016
71. **Lewis DA.** The re-emergence of untreatable gonorrhoea: a public health nightmare for the 21<sup>st</sup> Century?" **Lansdowne Public Lecture**, University of Victoria, Canada, 4 April 2017
72. **Lewis DA.** Antimicrobial resistance in *Neisseria gonorrhoeae*: evolutionary genius and the public health response. **Lansdowne University Lecture**, University of Victoria, Canada, 5 April 2017
73. **Lewis DA.** Scanning the horizon: anticipated and threatened STI outbreaks within MSM communities. **Symposium presentation** at the STI and HIV World Congress (Joint Meeting of the 22<sup>nd</sup> Meeting of the International Society for STD Research and the 18<sup>th</sup> International Union against Sexually Transmitted Infections World Congress), Rio de Janeiro, Brazil, 9-12 July 2017
74. **Lewis DA.** Treatment guidelines for genital Herpes simplex infection. **Invited talk** at the WHO Workshop on the new WHO treatment guidelines and on STI surveillance and estimation tools, STI and HIV World Congress (Joint Meeting of the 22<sup>nd</sup> Meeting of the International Society for STD Research and the 18<sup>th</sup> International Union against Sexually Transmitted Infections World Congress), Rio de Janeiro, Brazil, 9-12 July 2017
75. **Lewis DA.** Therapeutic challenges 2017. **Invited talk** at the IUSTI Advanced Course 2017: Test and Treatment of STIs, Helsinki, Finland, 30-31 August, 2017
76. **Lewis DA.** What is an STI? **Plenary presentation** at the 31st IUSTI-Europe Congress, Helsinki, Finland, 31 August-2 September, 2017
77. **Lewis DA.** New treatments for gonorrhoea. **Invited talk** at the 2017 International Forum on Gonococcal Infections and Resistance, Shenzhen, China, 17-19 September 2017
78. **Lewis DA.** Trichomoniasis: is it underestimated? **Symposium presentation** at the 22<sup>nd</sup> Annual Scientific Sessions of the Sri Lanka College of Sexual Health and HIV Medicine, Colombo, Sri Lanka, 5-7 October 2017
79. **Lewis DA.** Treating gonorrhoea in the absence of cephalosporins: Practical considerations and future options. **Symposium presentation** at the Australasian Sexual Health Conference, Canberra, Australia, November 7-9, 2017

80. **Lewis DA.** Public health challenges of sexually transmitted infections. **Invited talk** at the Centre for Infectious Diseases and Microbiology-Public Health's Annual Colloquium, Westmead, Australia, November 24, 2017
81. **Lewis DA.** Chlamydia, HIV pre-exposure prophylaxis and declining condom use. **Symposium presentation** at the Australian Chlamydia Conference, Sydney, Australia, 21-22 November, 2018
82. **Lewis DA.** What are sexually transmitted infections? **Invited talk** at the Hong Kong Society of Dermatology and Venereology's Annual Scientific Meeting, Hong Kong, China, 23 – 24 June 2018
83. **Lewis DA.** *Mycoplasma genitalium* in females. **Invited talk** at the Hong Kong Society of Dermatology and Venereology's Annual Scientific Meeting, Hong Kong, China, 23 – 24 June 2018
84. **Lewis DA.** Antimicrobial resistance and new treatment options for gonorrhoea. **Invited talk** at the Hong Kong Society of Dermatology and Venereology's Annual Scientific Meeting, Hong Kong, China, 23 – 24 June 2018
85. **Lewis DA.** What is an STI? **Keynote lecture** at the 42nd National Conference of Indian Association for the Study of STD & AIDS, New Delhi, India, 11-14 October 2018
86. **Lewis DA.** World Health Organization guidelines for genital herpes. **Invited talk** at the 42nd National Conference of Indian Association for the Study of STD & AIDS, New Delhi, India, 11-14 October 2018
87. **Lewis DA.** Treatment strategies in an era of extensively-drug resistant gonorrhoea. **Invited lecture** at the Thai Red Cross AIDS Research Centre, Bangkok, Thailand, 16 October 2018
88. **Lewis DA.** Drug resistance in gonorrhoea. **Invited talk** at the PASHNET educational and networking event, Sydney, Australia, 15 September 2018
89. **Lewis DA.** The Value of Molecular Tests to Diagnose and Detect Ciprofloxacin Susceptible Gonorrhoea in Clinical Practice. **Invited talk** at the 'Conserving the frontline: rapid AMR testing for gonorrhoea' SpeedX Educational Dinner, Auckland, New Zealand, 1 November 2018
90. **Lewis DA.** Syphilis: a historical overview. **Pre-Congress symposium presentation** at STI and HIV World Congress (Joint Meeting of the 23<sup>rd</sup> Meeting of the International Society for STD Research and the 20<sup>th</sup> International Union against Sexually Transmitted Infections World Congress), Vancouver, Canada, 14-17 July 2019
91. **Lewis DA.** Changes to guidelines for treatment of gonorrhoea and their role in gonorrhoea control. **Symposium presentation** at the 2019 Australasian Sexual Health Conference, Perth, Australia, 16-18 September 2019.

92. **Lewis DA.** The clinical role of *Mycoplasma genitalium* infection: reflections on an emerging STI. **Symposium presentation** at the 2019 Australasian Sexual Health Conference, Perth, Australia, 16-18 September 2019.
93. **Lewis DA.** The resurgence of syphilis: what have we learned and how can we respond? **Plenary lecture** at the XII Congress of the Brazilian STD Society, VIII Brazilian AIDS Congress and III Latin-American Congress on STI/HIV/AIDS, Foz do Iguaçu, Brazil, 22-25 September 2019
94. **Lewis DA.** Emerging antimicrobial resistance in STI pathogens, the way forward. **Plenary presentation** at the 8<sup>th</sup> Federation of Infectious Diseases Societies of Southern Africa Congress, Johannesburg, South Africa, 7-9 November 2019
95. **Lewis DA.** Uncommon manifestations of common STIs: diagnostics and treatment. **Symposium presentation** at the 8<sup>th</sup> Federation of Infectious Diseases Societies of Southern Africa Congress, Johannesburg, South Africa, 7-9 November 2019
96. **Lewis DA.** New treatment options for *Neisseria gonorrhoeae* in the era of emerging antimicrobial resistance. **Symposium presentation** at the 49<sup>th</sup> Annual Conference of the Indian Association of Dermatologists, Venereologists and Leprologists, Virtual Conference, 5-7 February 2021
97. **Lewis DA.** Gonorrhoea: is there a state of the art? **Invited talk** at the IUSTI-Europe Advanced Course, held as a pre-Congress event at STI & HIV 2021 World Congress, Virtual Meeting (Joint Meeting of the 24<sup>th</sup> Meeting of the International Society for STD Research and the 22<sup>nd</sup> International Union against Sexually Transmitted Infections World Congress), 14-17 July 2021.
98. **Lewis DA.** Genital ulcer disease: recommendations and evidence. **Symposium talk** at the STI & HIV 2021 World Congress (Joint Meeting of the 24<sup>th</sup> Meeting of the International Society for STD Research and the 22<sup>nd</sup> International Union against Sexually Transmitted Infections World Congress), Virtual Meeting, 14-17 July 2021.
99. **Lewis DA.** Genital ulcer disease: recommendations and evidence. **Invited talk** at the 'Updated WHO guidelines for management of symptomatic STIs' webinar for the WHO South-East Asia Region, 27 September 2021.
100. **Lewis DA.** Managing gonorrhoea that persists following ceftriaxone treatment. **Invited talk** at the IUSTI-Europe STI Course, 23rd IUSTI World Congress, Victoria Falls, Zimbabwe, 4-7 September 2022
101. **Lewis DA.** Ulcer management. **Invited talk** at the IUSTI-Europe STI Course Joint Session with WHO, 23rd IUSTI World Congress, Victoria Falls, Zimbabwe, 4-7 September 2022
102. **Lewis DA.** Imagine a world in 10-15 years if we did nothing today about NG-AMR. **Invited talk** at the FIND Sponsored Breakfast Symposium, 23rd IUSTI World Congress, Victoria Falls, Zimbabwe, 4-7 September 2022

103. **Lewis DA.** Motion: Rapid diagnostic testing for STIs will make syndromic management a thing of the past: **Debate presentation against the motion**, 23rd IUSTI World Congress, Victoria Falls, Zimbabwe, 4-7 September 2022
104. **Lewis DA.** Stepping up: how to become an effective leader. **Invited talk** for the International Society for Infectious Diseases' Emerging Leaders' Program. Virtual meeting, 30 September 2022
105. **Lewis DA** and Von Gottberg A. New approaches to diagnosis and treatment. **Pre-Congress Workshop**, 22<sup>nd</sup> International Pathogenic Neisseria Conference, Cape Town, South Africa, 9-14 October 2022
106. **Lewis DA.** Immune response to natural infection. **Invited talk** at a GSK Scientific Workshop, 22<sup>nd</sup> International Pathogenic Neisseria Conference, Cape Town, South Africa, 9-14 October 2022
107. **Lewis DA.** Resurgence of syphilis. **Symposium talk** at the 19th International Congress on Infectious Diseases, Kuala Lumpur, Malaysia, 17-20 November 2022.
108. **Lewis DA.** Emerging and re-emerging STIs in the Asia-Pacific region. **Symposium talk** at the 25th World Congress of Dermatology, Singapore, 3-8 July 2023.
109. **Lewis DA,** Herpes simplex virus (HSV) infections. **Oral presentation** at the World Health Organization pre-Congress session entitled 'What's new in STI diagnostics and point-of-care testing for STIs' at the STI & HIV 2023 World Congress (Joint Meeting of the 26<sup>th</sup> Meeting of the International Society for STD Research and the 24<sup>th</sup> International Union against Sexually Transmitted Infections World Congress), Chicago, USA, 24-27 July 2023.
110. **Lewis DA.** Will STI vaccines replace antimicrobials? **Symposium talk** at the STI & HIV 2023 World Congress (Joint Meeting of the 26<sup>th</sup> Meeting of the International Society for STD Research and the 24<sup>th</sup> International Union against Sexually Transmitted Infections World Congress), Chicago, USA, 24-27 July 2023
111. **Lewis DA.** Self-test and autonomy: how to reach individuals and ensure linkage with health care services? **Plenary presentation** at the joint meeting of the 14th Congress of the Brazilian STD Society, the 10th Brazilian AIDS Congress and the 5th Latin America Congress on STIs, HIV and AIDS, Florianopolis, Brazil, 4-7 October 2023
112. **Lewis DA.** The clinical role of *Mycoplasma genitalium* infection: reflections on an emerging STI. **Symposium presentation** at the joint meeting of the 14th Congress of the Brazilian STD Society, the 10th Brazilian AIDS Congress and the 5th Latin America Congress on STIs, HIV and AIDS, Florianopolis, Brazil, 4-7 October 2023
113. **Lewis DA.** Rapid tests for syphilis: new advantages. **Invited presentation** for the pre-Congress Advanced International Union against Sexually Transmitted Infections Europe

Course, 36<sup>th</sup> International Union against Sexually Transmitted Infections Europe Congress, Valetta, Malta, 26-28 October 2023

114. **Lewis DA.** Sexually transmissible infections: a new paradigm? **Plenary presentation** at the 36<sup>th</sup> International Union against Sexually Transmitted Infections Europe Congress, Valetta, Malta, 26-28 October 2023
115. **Lewis DA.** Prevention of STIs: doxycycline and meningococcal B vaccination. **Symposium presentation** at the 10<sup>th</sup> Federation of Infectious Diseases Societies of Southern Africa Congress, Johannesburg, South Africa, 30 May to 1 June 2024
116. **Lewis DA.** Review of treatment options and needs. **Invited talk** at the GARDP Expert Meeting on *Mycoplasma genitalium*, Sydney, Australia, 16 September 2024
117. **Lewis DA.** Evidence for different treatment recommendations in different settings. **Symposium presentation** in the WHO-organised symposium on ‘Strategies to outsmart antibiotic resistance in gonorrhoea’, 25<sup>th</sup> International Union against Sexually Transmitted Infections World Congress, Sydney, Australia, 17-20 September 2024
118. **Lewis DA.** Will introduction of Bexsero vaccination reduce gonorrhoea among gay and bisexual men-who-have-sex-with-men. **Invited presentation** for the Centre for Infectious Diseases and Microbiology-Public Health Annual Colloquium, Sydney, Australia, 29 November 2024
119. **Lewis DA.** Current and future treatment of *Neisseria gonorrhoeae*. **Symposium presentation** in the WHO-organised symposium on ‘Optimising Diagnosis and Treatment of STIs’, 20<sup>th</sup> International Congress on Infectious Diseases, Cape Town, South Africa, 3-6 December 2024
120. **Lewis DA.** *Mycoplasma genitalium* co-infection in men with symptomatic gonococcal urethritis. **Symposium presentation** at the joint meeting of the 15th Congress of the Brazilian STD Society, the 11th Brazilian AIDS Congress and the 6th Latin-American Congress on STIs, HIV and AIDS, Rio de Janeiro, Brazil, 3-6 June 2025
121. **Lewis DA.** Resistant *Neisseria gonorrhoeae*: how big is the problem? **Invited Talk** at the pre-Congress IUSTI Advance Course, 38<sup>th</sup> International Union against Sexually Transmitted Infections Europe Congress, Athens, Greece, 9-11 October 2025
122. **Lewis DA.** Why is it so important for IUSTI to build up and support the African region? **Symposium presentation** at the 38<sup>th</sup> International Union against Sexually Transmitted Infections Europe Congress, Athens, Greece, 9-11 October 2025
123. **Lewis DA.** Drug resistant STIs: breaking down the latest evidence? **WHO Symposium presentation** at the 38<sup>th</sup> International Union against Sexually Transmitted Infections Europe Congress, Athens, Greece, 9-11 October 2025

124. **Lewis DA.** Sexually transmissible infections: why terminology matters. **Invited Talk** for the Centre for Infectious Diseases and Microbiology-Public Health's webinar, Sydney, 31 October 2025